|
Bridging the Gap: Refining Myeloma Precursors and Their Risk of Progression Through Genomics Journal of Clinical Oncology, Volume 44, Issue 3, Page 135-138, January 2026. <br/> 2026-01-20T08:00:00Z Smell Journal of Clinical Oncology, Volume 44, Issue 3, Page 252-253, January 2026. <br/> 2026-01-20T08:00:00Z Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study Journal of Clinical Oncology, Volume 44, Issue 3, Page 164-175, January 2026. <br/> 2026-01-20T08:00:00Z Genomics Define Malignant Transformation in Myeloma Precursor Conditions Journal of Clinical Oncology, Volume 44, Issue 3, Page 188-199, January 2026. <br/> 2026-01-20T08:00:00Z Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial Journal of Clinical Oncology, Volume 44, Issue 3, Page 176-187, January 2026. <br/> 2026-01-20T08:00:00Z Management of Cancer During Pregnancy: ASCO Guideline Journal of Clinical Oncology, Volume 44, Issue 3, Page 200-251, January 2026. <br/> 2026-01-20T08:00:00Z Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial Journal of Clinical Oncology, Volume 44, Issue 3, Page 143-152, January 2026. <br/> 2026-01-20T08:00:00Z Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026) Journal of Clinical Oncology, Volume 44, Issue 3, Page 153-163, January 2026. <br/> 2026-01-20T08:00:00Z Tumultuous Development of Venetoclax in t(11;14) Multiple Myeloma Journal of Clinical Oncology, Volume 44, Issue 3, Page 139-142, January 2026. <br/> 2026-01-20T08:00:00Z Noncomparative Comparisons: The Paradox of Randomized Noncomparative Trials Journal of Clinical Oncology, Volume 44, Issue 3, Page 257-259, January 2026. <br/> 2026-01-20T08:00:00Z Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial Journal of Clinical Oncology, Volume 44, Issue 3, Page 254-256, January 2026. <br/> 2026-01-20T08:00:00Z Reply to: Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial Journal of Clinical Oncology, Volume 44, Issue 3, Page 256-257, January 2026. <br/> 2026-01-20T08:00:00Z Reply to: Noncomparative Comparisons: The Paradox of Randomized Noncomparative Trials Journal of Clinical Oncology, Volume 44, Issue 3, Page 259-260, January 2026. <br/> 2026-01-20T08:00:00Z Mother's Grief Journal of Clinical Oncology, Ahead of Print. <br/> North Star Journal of Clinical Oncology, Ahead of Print. <br/> A Chance to Heal With Cold Hard Steel Journal of Clinical Oncology, Ahead of Print. <br/> |
Fremanezumab in Children and Adolescents with Episodic Migraine
New England Journal of Medicine, Volume 394, Issue 3, Page 243-252, January 15, 2026.
Subretinal Photovoltaic Implant to Restore Vision in Geographic Atrophy Due to AMD New England Journal of Medicine, Volume 394, Issue 3, Page 232-242, January 15, 2026.
Medical Management and Revascularization for Asymptomatic Carotid Stenosis New England Journal of Medicine, Volume 394, Issue 3, Page 219-231, January 15, 2026.
Popeye Sign in Transthyretin Amyloidosis New England Journal of Medicine, Volume 394, Issue 3, Page 310-311, January 15, 2026.
2024–2025 Covid-19 Vaccine Outcomes in U.S. Veterans New England Journal of Medicine, Volume 394, Issue 3, Page 306-307, January 15, 2026.
Borrelia burgdorferi Infection and Erythema Migrans New England Journal of Medicine, Volume 394, Issue 3, Page 302-303, January 15, 2026.
Managing Asymptomatic Carotid Stenosis New England Journal of Medicine, Volume 394, Issue 3, Page 296-297, January 15, 2026.
Granulomatosis with Polyangiitis New England Journal of Medicine, Volume 394, Issue 3, Page 281-281, January 15, 2026.
The Things We Carry New England Journal of Medicine, Volume 394, Issue 3, Page 216-217, January 15, 2026.
Financing Telehealth — Moving Beyond Payment Parity New England Journal of Medicine, Volume 394, Issue 3, Page 211-213, January 15, 2026.
DB-OTO Gene Therapy for Inherited Deafness New England Journal of Medicine, Ahead of Print.
Nivolumab for Resected Stage III or IV Melanoma at 9 Years New England Journal of Medicine, Ahead of Print.
Immediate or Deferred Nonculprit-Lesion PCI in Myocardial Infarction New England Journal of Medicine, Ahead of Print.
A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy New England Journal of Medicine, Ahead of Print.
Therapy for Atrial Fibrillation in Patients with Drug-Eluting Stents New England Journal of Medicine, Ahead of Print.
Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction New England Journal of Medicine, Ahead of Print.
Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk New England Journal of Medicine, Ahead of Print.
Sibeprenlimab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial New England Journal of Medicine, Ahead of Print.
Prime Editing for p47phox-Deficient Chronic Granulomatous Disease New England Journal of Medicine, Ahead of Print.
Ketamine or Etomidate for Tracheal Intubation of Critically Ill Adults New England Journal of Medicine, Ahead of Print.
Ianalumab plus Eltrombopag in Immune Thrombocytopenia New England Journal of Medicine, Ahead of Print.
Changing Role of Adjuvant Therapy in Stage III Melanoma New England Journal of Medicine, Ahead of Print.
The Essential Role of States in Protecting Immunization Access New England Journal of Medicine, Ahead of Print.
Conflation of Contraception and Abortion — Implications for Access to Contraceptives New England Journal of Medicine, Ahead of Print.
|
CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia
In 11 patients with multirefractory autoimmune hemolytic anemia, CD19 CAR T-cell therapy resulted in a complete response, drug-free remission lasting a median of 11.5 months, and expected toxic effects. 2026-01-15
Automatic Medicare Coverage for New Medical Technologies — Here We Go Again Congress is considering bills that would substantially expand Medicare coverage of certain products. The legislation could undermine CMS’s authority to implement evidence-based coverage policies. 2026-01-15
Reducing Tobacco Use Worldwide: Smokeless Tobacco and Oral Cancer in Global Perspective Despite use of smokeless tobacco products by more than 360 million people globally and increasing incidence of oral cancers, research and policies on these products have lagged behind those for cigarettes. 2026-01-15
The Things We Carry The ID, the pen, the epinephrine, the scalpel are the nonnegotiables, the necessities for any hospital shift. But they are not the only things a physician carries, and certainly not the most burdensome. 2026-01-15
Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia In relapsed or refractory T-cell acute lymphoblastic leukemia, off-the-shelf allogeneic base-edited CAR7 T cells mediated responses in 11 patients, enabling stem-cell transplantation in 9 patients in deep remission. 2026-01-08
My Brother’s Sister When she finds herself caring for a patient the same age and with the same rare disease as her brother, a physician discovers the impossibility of compartmentalizing her various identities. 2026-01-08
Collision Lesion An 80-year-old woman presented with a skin lesion on her left arm. Examination showed a brown lesion with eccentric hyperpigmented asymmetric globules adjacent to a second, pink lesion with well-defined borders. 2026-01-08
Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC In EGFR-mutated non–small-cell lung cancer, first-line osimertinib plus platinum–pemetrexed extended overall survival to 47.5 months, as compared with 37.6 months with osimertinib alone, but increased the risk of adverse events. 2026-01-01
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR-Mutated Advanced NSCLC In EGFR-mutated advanced non–small-cell lung cancer with progression after EGFR-TKI therapy, sacituzumab tirumotecan led to better progression-free and overall survival outcomes than chemotherapy. 2026-01-01
Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab In drug-resistant extramedullary myeloma, dual treatment with talquetamab and teclistamab produced a response in 79% of patients, and 12-month overall survival was 74%; however, grade 3 or 4 adverse events were common. 2026-01-01
Where Do I Put This? Grieving over a beloved patient who’d invited her into the private, sacred space of her planned day of death, a palliative care physician finds it hard to switch gears as she sits in a PTA meeting. 2026-01-01
Navigating the Evolving Landscape of EGFR-Mutated NSCLC Combination chemotherapy has long been a mainstay of cancer treatment, although early mechanism-based therapies showed little promise. In 1970, Vincent T. DeVita and colleagues revolutionized oncology with their finding that combination regimens could induce long-term remission in patients with Hodgkin’s disease, even at advanced stages.1 More than 50... 2026-01-01
Direct-Acting Antiviral Agents in Hepatitis C–Associated Indolent Lymphomas In an update of the BArT study, direct-acting antivirals led to durable responses in HCV-associated indolent B-cell lymphomas, with 6-year progression-free survival of 66% and no relapses after a complete response. 2026-01-01
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer In muscle-invasive bladder cancer, ctDNA-guided atezolizumab led to longer disease-free survival (9.9 vs. 4.8 months), as well as to longer overall survival (32.8 vs. 21.1 months), than placebo among ctDNA-positive patients. 2025-12-18
Noninferiority of One HPV Vaccine Dose to Two Doses In this trial, one dose of an HPV vaccine was noninferior to two doses in preventing HPV type 16 or 18 infection. 2025-12-18
Evidence to Action — Single-Dose HPV Vaccination and Cervical HPV Infection Kreimer and colleagues now report in the Journal1 the results of the ESCUDDO trial, which showed that the efficacy of a single dose of either a bivalent human papillomavirus (HPV) vaccine or a nonavalent formulation was similar to that of the standard two-dose schedule. This randomized trial... 2025-12-18
Reducing Tobacco Use Worldwide: The Epidemic of Tobacco Harms among People with Mental Health Conditions High rates of tobacco use among people with mental health conditions contribute to their increased morbidity and mortality, but tobacco cessation interventions can be effective in this population. 2025-12-18
Merkel-Cell Carcinoma A 72-year-old woman presented with a 3.5-month history of an enlarging, painless lump on her cheek. Examination showed a dome-shaped, reddish nodule on the left cheek, with a shiny surface and central hemorrhagic crust. 2025-12-18
ctDNA-Guided Therapy in Bladder Cancer — Ready? Liquid-biopsy analysis for circulating tumor DNA (ctDNA) has the potential to transform cancer care through personalized, noninvasive disease monitoring. In bladder cancer, ctDNA is a strong prognostic biomarker after cystectomy and may guide adjuvant treatment decisions. Retrospective and prospective studies show that ctDNA positivity is linked to an increased risk... 2025-12-18
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer In HER2-expressing urothelial cancer, disitamab vedotin plus toripalimab doubled the median progression-free survival, increased the median overall survival, and reduced adverse events as compared with chemotherapy. 2025-12-11
|
|
| ||
|
[Editorial] Cancer consequences of the HIV funding crisis
Reductions in development assistance funding by previous major donors—the USA, the UK, France, and Germany—have led to substantial challenges to global HIV control in 2025. Against this stark backdrop, World AIDS Day 2025 was commemorated globally on Dec 1, 2025. UNAIDS released a report ahead of the day detailing the impact of the unprecedented changing international aid landscape on global HIV control programmes worldwide, particularly in low-income and middle-income countries. Failure to meet the 2030 global HIV targets could result in an additional 3·3 million new HIV infections between 2025 and 2030, according to the report. Thu, 01 Jan 2026 00:00:00 -0800
[Comment] Is PORTEC-4a the tipping point in endometrial cancer management? The PORTEC-4a trial1 provides, to the best of our knowledge, the first prospective, randomised evidence that a molecular integrated risk profile can safely guide adjuvant therapy decisions in high-intermediate risk endometrial cancer, reinforcing the rationale for incorporating molecular classification into clinical practice. According to Anne Sophie V M van den Heerik and colleagues’ findings in the Lancet Oncology,2 a refined molecular stratification supports a more tailored adjuvant treatment, enabling either de-escalation or intensification of radiotherapy based on individual tumour biology. Thu, 01 Jan 2026 00:00:00 -0800
[Comment] Micrometastatic axillary disease after neoadjuvant treatment In The Lancet Oncology, Giacomo Montagna and colleagues1 report the results of the large international retrospective OPBC-07/microNAC study, comparing the oncological outcomes and 3-year axillary recurrence rate for 1585 patients with breast cancer and residual micrometastases at axillary staging after neoadjuvant chemotherapy with and without completion axillary lymph node dissection (ALND). The feasibility and safety of axillary surgery de-escalation in patients with breast cancer who are at high risk of arm morbidity after ALND is an important clinical question. Thu, 01 Jan 2026 00:00:00 -0800
[Comment] The importance of preventing occupational cancer Cancer is a leading cause of death globally, and the number of cancer cases is rising in most countries. This increase presents a substantial challenge for health systems across the globe, as extensive resources are required for the diagnosis and treatment of cancer patients. Fri, 05 Dec 2025 23:30:01 +0000
[Comment] Has the limit been reached in treatment of unresectable oesophageal squamous cell carcinoma? SKYSCRAPER-08, a randomised, double-blind, placebo-controlled, phase 3 trial, marks a milestone in the treatment of oesophageal squamous cell carcinoma.1 Patients were randomly assigned to receive tiragolumab (a TIGIT inhibitor) plus atezolizumab (a PD-L1 inhibitor) and chemotherapy (paclitaxel and cisplatin) or to receive placebo and chemotherapy. Median progression-free survival was 6·2 months (95% CI 5·7–7·2) with tiragolumab plus atezolizumab versus 5·4 months (4·4–5·5) without (hazard ratio [HR] 0·56, 95% CI 0·45–0·70; p<0·0001), whereas median overall survival was 15·7 months (95% CI 13·3–20·4) versus 11·1 months (9·6–13·6; HR 0·70, 95% CI 0·55–0·88; p=0·0024). Thu, 01 Jan 2026 00:00:00 -0800
[Comment] Artificial intelligence in pancreatic cancer detection: from premise to practice Pancreatic ductal adenocarcinoma (PDAC) remains among the deadliest cancers globally, primarily because symptoms typically appear at a late stage, resulting in diagnosis when curative treatment is no longer possible. Furthermore, detection of PDAC and other periampullary cancers on CT scans is challenging and requires specialised radiological expertise. However, even experienced radiologists miss early-stage tumours on CT scans; in a 2023 study, 15 expert radiologists achieved an average sensitivity of just 79·6% when reading contrast-enhanced CTs for PDAC. Thu, 20 Nov 2025 23:30:04 +0000
[Comment] The promise of scalable symptom surveillance with stepped collaborative care in oncology Guidelines for managing deleterious symptoms from cancer and its treatments have been largely underused in practice. To address this problem, the National Cancer Institute launched the Improving the Management of Symptoms During and Following Cancer Treatment (IMPACT) consortium,1 an alliance of three research centres leading large-scale trials of electronic patient-reported outcome measure (ePROM) symptom surveillance and management systems. Andrea L Cheville and colleagues2 report findings from one IMPACT trial, showing positive effects of an enhanced, electronic health record (EHR)-facilitated cancer symptom control (E2C2) intervention on patients' and survivors' symptom burden and health-care use. Mon, 01 Dec 2025 23:30:03 +0000
[Comment] De-escalation of adjuvant radiotherapy in HPV-associated oropharyngeal cancer HPV-associated oropharyngeal carcinoma has a distinct biology and responds favourably to primary radiation (and surgery)-based treatments. The long-term survival benefit is, however, offset by chronic detrimental impact on health-related quality of life for cancer survivors due to treatment-related toxic effects such as dysphagia and xerostomia. Consequently, many toxicity-mitigating de-escalation methods are being explored for HPV-associated oropharyngeal carcinoma.1 Minimally invasive primary transoral surgery followed by de-intensification of post-operative (chemo) radiation depending on pathological risk assessment is one such investigational approach. Thu, 01 Jan 2026 00:00:00 -0800
[Comment] Retraction and republication—De-escalation of adjuvant radiotherapy in HPV-associated oropharyngeal cancer In September, 2025, The Lancet Oncology published results of the phase 3 MC1675 study on de-escalated adjuvant radiotherapy versus standard adjuvant treatment for human papillomavirus-associated oropharyngeal squamous cell carcinoma.1 After publication, the corresponding author alerted us to numerical errors present in table 1 caused by a mistranscription of the number of patients in each category of nodal staging by AJCC 7th edition staging and AJCC 8th edition staging. These errors did not affect other data, findings, or interpretation in the paper and we have thus corrected the online version as of Dec 22, 2025. Thu, 01 Jan 2026 00:00:00 -0800
[Correspondence] The PREOPANC-2 trial in resectable and borderline resectable pancreatic cancer The ESPAC1 and ESPAC1-Plus trials in 2001 and 2004 respectively established surgery and six months of adjuvant chemotherapy as the standard of care for empirically resectable pancreatic cancer. This protocol was confirmed repeatedly over the last 25 years, leading to an enormous increase in the volume of patients being treated with surgery and adjuvant chemotherapy. The development of improved cancer treatment strategies requires that randomised controlled trials that aimed to be practice changing should include the best current standard of care as the control group. Thu, 01 Jan 2026 00:00:00 -0800
[Correspondence] The PREOPANC-2 trial in resectable and borderline resectable pancreatic cancer We congratulate Quisette P Janssen and colleagues on the phase 3 PREOPANC-2 trial.1 PREOPANC-2 was the successor of the phase 3 PREOPANC-1, which showed improved overall survival following pre-operative chemoradiotherapy and surgery versus surgery for patients with anatomically resectable or borderline resectable pancreatic ductal adenocarcinoma. In light of the superiority for post-operative FOLFIRINOX versus gemcitabine and multiple rationales for pre-operative multi-agent chemotherapy, PREOPANC-2 tested the hypothesis that overall survival was longer following pre-operative FOLFIRINOX versus the gemcitabine-based chemoradiotherapy PREOPANC-1 approach. Thu, 01 Jan 2026 00:00:00 -0800
[Correspondence] The PREOPANC-2 trial in resectable and borderline resectable pancreatic cancer – Authors' reply We thank John P Neoptolemos and colleagues for their letter. They state that the ESPAC-1 trial set the standard of care for adjuvant therapy in resectable pancreatic cancer.1 However, ESPAC-1 set the standard of care for resected pancreatic cancer, including only those patients who had no occult metastases at surgery, underwent a resection, recovered from surgery, had no early recurrence, and remained fit for adjuvant treatment. In the adjuvant group of nine randomised controlled trials comparing neoadjuvant with adjuvant therapy, only 80% of all patients with resectable pancreatic cancer became patients with resected pancreatic cancer. Thu, 01 Jan 2026 00:00:00 -0800
[Correspondence] Tumour genetics and thyroid cancer staging We read with interest the Comment by Susan C Pitt and Megan Haymart1 on our Article on genetic modification of the American Joint Committee on Cancer (AJCC) staging system in papillary thyroid cancer2 and hold the following conservative opinions. Thu, 01 Jan 2026 00:00:00 -0800
[Corrections] Correction to Lancet Oncol 2025; 26: 187–99 van der Lei S, Puijk RS, Dijkstra M, et al. Thermal ablation versus surgical resection of small-size colorectal liver metastases (COLLISION): an international, randomised, controlled, phase 3 non-inferiority trial. Lancet Oncol 2025; 26: 187–99—In this Article, all data labelled as IQR in the Summary, table 1 legend, and Results should have been labelled as range; figure 2 has also been updated. These corrections have been made to the online version as of Dec 22, 2025. Thu, 01 Jan 2026 00:00:00 -0800
[Corrections] Correction to Lancet Oncol 2025; 26: 1227–39 Ma D, Price K, Moore E, et al. De-escalated adjuvant radiotherapy versus standard adjuvant treatment for human papillomavirus-associated oropharyngeal squamous cell carcinoma (MC1675): a phase 3, open-label, randomised controlled trial. Lancet Oncol 2025; 26: 1227–39—In table 1 of this Article, the number of participants in each AJCC 8th edition N stage and AJCC 7th edition N stage at baseline have been corrected. This correction has been made as of Dec 22, 2025. Thu, 01 Jan 2026 00:00:00 -0800
[Corrections] Correction to Lancet Oncol 2025; 26: e477–87 Tang L-L, Huang C-L, Lin S-J, et al. Primary target volume delineation for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas. Lancet Oncol 2025; 26: e477–87—In this Policy Review, the first sentence of Recommendation 3.3 should have read, “Posteriorly delineate the anterior third of the clivus (the cortex) if uninvolved (usually for T1 and T2 disease) and include the whole clivus (inferior, posterior column, up to the posterior clinoid process) for any clival involvement (usually for T3 and T4 disease).” This correction has been made to the online version as of Dec 22, 2025. Thu, 01 Jan 2026 00:00:00 -0800
[News] Carcinogenicity of atrazine, alachlor, and vinclozolin From October to November, 2025, a Working Group of 22 scientists from 12 countries met at the International Agency for Research on Cancer (IARC) in Lyon, France, to finalise their evaluation of the carcinogenicity of atrazine, alachlor, and vinclozolin. Fri, 21 Nov 2025 08:00:02 +0000
[News] Study links ultra-processed food consumption with bowel polyps in women younger than 50 years New research by Andrew T Chan (Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA) and colleagues published in JAMA Oncology shows that younger women (aged ≤50 years) who eat the highest proportions of ultra-processed foods (UPFs) are at a 45% increased risk of developing bowel polyps that can later develop into colorectal cancer. UPFs are novel branded products made from inexpensive industrial ingredients such as hydrogenated oils, protein isolates or glucose or fructose syrup, and cosmetic food additives (including dyes, artificial sweeteners, and emulsifiers). Thu, 20 Nov 2025 23:30:01 +0000
[News] WHO sets new global standard for child‑friendly cancer drugs On Nov 6, 2025, WHO published six new target product profiles for child‑friendly formulations of essential cancer medicines. The profiles aim to support the development of age‑appropriate formulations and close gaps in paediatric cancer care. Thu, 20 Nov 2025 23:30:01 +0000
[News] Europe is falling behind on targets to address AMR Antimicrobial resistance (AMR) is causing more than 35 000 deaths per year across Europe. According to estimates by the European Centre for Disease Prevention and Control (ECDC), based on 2024 data submitted by all countries in the EU and European Economic Area, Europe has met only one of five targets set to tackle the issue. Thu, 27 Nov 2025 23:30:04 +0000
[News] Gavi hits HPV vaccine milestone early but concerns surround future funding Gavi, the Vaccine Alliance, a public–private global health partnership with the goal of increasing access to immunisation in developing countries, is celebrating after working with lower-income countries to reach a key target to vaccinate millions of girls with the human papillomavirus (HPV) vaccine for cervical cancer in mid-November, 2025—6 weeks ahead of its original 3-year target. Thu, 27 Nov 2025 23:30:02 +0000
[News] New South Wales expands cancer coverage for firefighters On Nov 21, 2025, a ministerial media release announced a new legislation passed through Australian Parliament, expanding presumptive workers' compensation coverage for firefighters diagnosed with cancer. The new legislation extends the current list of 12 recognised malignancies in New South Wales, Australia, to include ten new cancers, including primary site lung, pancreatic, thyroid, and skin cancers. Reproductive cancers including cervical, ovarian, uterine, vaginal, vulval, and penile were also included. Thu, 27 Nov 2025 23:30:04 +0000
[News] UK–US drug pricing deal to cost NHS £3 billion as NICE increases new medicines threshold The UK has agreed a deal with the USA for a 0% tariff on pharmaceuticals in return for a 25% increase to the threshold at which the National Health Service (NHS) deems medicines to be cost-effective. Fri, 05 Dec 2025 23:30:01 +0000
[News] UK Government launches first Men's Health Strategy On Nov 19, 2025, the UK Government launched the first Men's Health Strategy for England. The policy paper noted that, over the past decade, healthy life expectancy for men has fallen by 1·5 years and that men in parts of the country with the most poverty die on average 10 years earlier than men in parts with the least poverty. Men are more likely than women to smoke, drink alcohol, or use drugs, and be overweight or have obesity. 19% of deaths in men over 35 years are attributable to smoking, seven percentage points higher than women in the same age group, and 68% of deaths from liver disease are in men. Thu, 11 Dec 2025 23:30:01 +0000
[Perspectives] Current landscape, successes, and key challenges in cancer vaccine clinical trials across the UK Cancer vaccines represent a transformative frontier in oncology, offering the potential to elicit durable and specific immune responses against tumour-associated or tumour-specific antigens. This technology has the potential to treat established malignancy, reduce tumour relapse, and even prevent cancer formation—improving survival outcomes. Advances in neoantigen discovery, mRNA vaccine platforms, and personalised immunotherapy have substantially enhanced the feasibility and efficacy of cancer vaccines across various malignancies. Thu, 01 Jan 2026 00:00:00 -0800
[Articles] Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial Individualised adjuvant treatment by molecular integrated risk profile is safe and effective for patients with high-intermediate risk endometrial cancer; it spared 46% of patients with a favourable profile from adjuvant treatment, and reduces both overtreatment and undertreatment. Thu, 01 Jan 2026 00:00:00 -0800
[Articles] Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study Vebreltinib showed antitumour activity in patients with MET amplification-driven advanced NSCLC who had previously received chemotherapy or were chemotherapy-naive. Further research is needed to validate these findings. Sat, 06 Dec 2025 08:00:01 +0000
[Articles] Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial Long-term follow-up confirms that radiotherapy followed by 12 cycles of adjuvant temozolomide without concurrent temozolomide during radiotherapy improves survival for individuals with aggressive IDHmt astrocytoma. Thu, 01 Jan 2026 00:00:00 -0800
[Articles] Oncological outcomes with and without axillary lymph node dissection in patients with residual micrometastases after neoadjuvant chemotherapy (OPBC-07/microNAC): an international, retrospective cohort study Overall, these results do not support ALND for all patients with ypN1mi on sentinel lymph node biopsy treated with nodal radiotherapy; however, tumour biology should be taken into account when considering ALND omission. Thu, 01 Jan 2026 00:00:00 -0800
[Articles] Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial Nivolumab plus docetaxel did not improve progression-free survival or overall survival versus placebo plus docetaxel in patients with ARPI-pretreated, chemotherapy-naive mCRPC. These findings do not support the use of combinations of anti-PD-1 immune checkpoint inhibitors and docetaxel in the treatment of unselected populations of patients with ARPI-pretreated, chemotherapy-naive mCRPC. Thu, 01 Jan 2026 00:00:00 -0800
[Articles] Cancer mortality rates by detailed occupation among US working-age adults between 2020 and 2023: a population-based study US cancer mortality rates among working-age adults vary substantially by sex, occupation, and cancer site, suggesting workplace-related exposures beyond carcinogens. These findings highlight the need to study how working conditions, structural inequities, and health-care access influence cancer mortality risk by occupation. Fri, 05 Dec 2025 23:30:01 +0000
[Articles] First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trial These results support the additional benefit of tiragolumab combined with atezolizumab and chemotherapy for patients with treatment-naive, locally advanced unresectable or metastatic oesophageal cancer. Further validation of tiragolumab plus atezolizumab and chemotherapy has been performed in the phase 3 SKYSCRAPER-08 trial (NCT04540211). Thu, 01 Jan 2026 00:00:00 -0800
[Articles] Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma (SKYSCRAPER-08): a randomised, double-blind, placebo-controlled, phase 3 trial Independent review facility-assessed progression-free survival and overall survival were significantly better in the tiragolumab plus atezolizumab and chemotherapy group compared with chemotherapy alone for unresectable locally advanced, unresectable recurrent, or metastatic oesophageal squamous cell carcinoma. These data support the rationale for exploring dual checkpoint inhibition added to chemotherapy for this group of patients with a high unmet need. Thu, 01 Jan 2026 00:00:00 -0800
[Articles] Artificial intelligence and radiologists in pancreatic cancer detection using standard of care CT scans (PANORAMA): an international, paired, non-inferiority, confirmatory, observational study AI demonstrated substantially improved PDAC detection on routine CT scans compared to radiologists on average, showing potential to detect cancer earlier and improve patient outcomes. Thu, 20 Nov 2025 23:30:01 +0000
[Articles] Electronic health record-facilitated symptom surveillance and collaborative care intervention in oncology (E2C2): a cluster-randomised, population-level, stepped-wedge, pragmatic trial Centralised EHR-facilitated, symptom surveillance and collaborative care management are more beneficial than symptom surveillance alone in reducing the population burden of SPPADE symptoms in oncology patients. Mon, 01 Dec 2025 23:30:01 +0000
[Policy Review] A comprehensive framework for glioma surgery by the PIONEER Consortium and RANO resect group, part 1: intraoperative recommendations for mapping, monitoring, and decision making In adult patients with newly diagnosed or recurrent diffuse glioma, more extensive resection is associated with longer progression-free and overall survival. Intraoperative mapping techniques are used to safely increase the extent of resection by locating, monitoring, and preserving the function of potentially infiltrated brain during surgery. However, there is no consensus on the indications for intraoperative mapping, the optimal functional tests to be used intraoperatively, or intraoperative decision making. Thu, 01 Jan 2026 00:00:00 -0800
[Policy Review] A comprehensive framework for glioma surgery by the PIONEER Consortium and RANO resect group, part 2: perioperative recommendations for neurological, language, functional, and quality-of-life assessment Historically, the assessment of surgical outcomes in patients with glioma has been focused on technical outcomes, such as volumetric analysis of the residual tumour, progression-free survival, and overall survival. Other outcomes, such as neurological deficits, can be challenging to assess in an objective, quantifiable, and comprehensive manner. As a result, no consensus is available on methods to systematically evaluate perioperative neurological, language, cognitive, and functional outcomes in patients with glioma. Thu, 01 Jan 2026 00:00:00 -0800
[Policy Review] International consensus recommendations and alignment of terminology for the histopathological diagnosis of extranodal extension in head and neck squamous cell carcinoma: an HN-CLEAR initiative Histopathologically detected extranodal extension leads to upstaging and treatment escalation in head and neck squamous cell carcinoma. There is considerable variation in the prevalence of histopathologically detected extranodal extension in comparable studies. The Head and Neck Cancer International Group, which includes 23 organisations managing patients with head and neck cancer, identified several challenges in evaluating histopathologically detected extranodal extension. Thus, the Head and Neck Consensus Language for Ease and Reproducibility (HN-CLEAR) and its global stakeholders prioritised developing diagnostic criteria and uniform terminology for histopathologically detected extranodal extension. Thu, 01 Jan 2026 00:00:00 -0800
[Review] Development of a core outcome set for adolescents and young adults with cancer Adolescents and young adults aged 15–39 years diagnosed with cancer are faced with unique challenges, which affect key developmental milestones and can create complex care needs. The aim of this study was to reach international consensus on the minimum set of outcomes to measure through the development of a core outcome set (COS). The COS development followed published methodological standards. A literature review and interviews with adolescents and young adults with cancer and health-care professionals generated a comprehensive list of 129 outcomes, spanning clinical and patient-reported outcomes relevant to adolescents and young adults with cancer. Thu, 01 Jan 2026 00:00:00 -0800
[Clinical Picture] High-output cardiac failure from a synovial sarcoma mimicking arteriovenous fistula A 30-year-old woman presented to the Vascular Anomalies Centre at Shanghai Ninth People's Hospital in February, 2021, for a worsening and painful left inguinal arteriovenous fistula, which had been diagnosis 7 years previously following a strain 10 years ago. Initial endovascular embolisation in 2014 provided only transient relief, with subsequent symptom recurrence, progressive deep vein thrombosis, limb oedema, and claudication. By 2018, she had developed orthopnoea indicative of cardiac failure and required continuous diuretics, having received only symptomatic care until her presentation. Thu, 01 Jan 2026 00:00:00 -0800
|
[Articles] Cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas: a multicentre, single-arm, lead-in phase 2 trial
Cabozantinib with temozolomide showed a meaningful clinical benefit and could potentially be a viable treatment option for patients with unresectable or metastatic leiomyosarcoma. Treatment was tolerable and did not reveal any new safety signals. 2026-01-16T23:30:02Z
[News] WHO on global taxation of alcoholic and sugar-sweetened drinks WHO is calling on governments to raise taxes on alcoholic beverages and sugary drinks after two new reports show both have become cheaper over the past few years. National tax policies should ensure these unhealthy products become less affordable over time, highlights WHO. However, the reports released on Jan 13, 2026, reveal that only 37 countries have achieved this trend for beer and only 34 for sugar-sweetened carbonated drinks. Allowing sugary drinks and alcohol to become more affordable will result in a rise in non-communicable diseases and injuries, warns WHO. 2026-01-15T23:30:01Z
[Articles] Pembrolizumab plus lenvatinib in recurrent gynaecological clear cell carcinoma (LARA): a multicentre, single-arm, phase 2 trial Pembrolizumab plus lenvatinib showed promising anti-tumour activity and manageable safety in patients with recurrent CCGC, including in patients with disease progression following previous treatment with anti-angiogenic therapy. These findings support further evaluation of this combination in randomised controlled trials. 2026-01-15T23:30:03Z
[Comment] Precision oncology in resected EGFR-mutant NSCLC The therapeutic landscape of early-stage EGFR-mutated non-small-cell lung cancer (NSCLC) has been irreversibly transformed by adjuvant EGFR tyrosine-kinase inhibitors.1 This paradigm shift began with the ADAURA trial, which established postoperative osimertinib as the first adjuvant targeted therapy to deliver durable survival benefit in molecularly defined NSCLC.2,3 Its effects extended beyond recurrence delay, providing clear evidence that early systemic intervention can improve cure rates and prevent metastatic relapse, especially in the brain. 2026-01-12T23:30:02Z
[Articles] Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial Aumolertinib showed substantial clinical benefits as adjuvant therapy in Chinese patients with stage II–IIIB EGFR-mutated NSCLC. The manageable safety profile of aumolertinib supports its suitability in the adjuvant setting. 2026-01-12T23:30:02Z
[Articles] Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial The significantly improved overall survival and patient-reported measures in CARTITUDE-4 reinforce the use of cilta-cel in treating relapsed or refractory multiple myeloma as early as after first relapse. 2026-01-07T23:30:02Z
[Comment] Media coverage and PATHFINDER2: hype, simplification, and free advertising The recent media coverage of interim results from the PATHFINDER2 study of GRAIL's Galleri multicancer detection blood test exemplifies a troubling and recurring trend in science communication: the commercially driven, premature framing of non-peer-reviewed data as proof of a transformative breakthrough. Released via an embargoed press statement on Oct 17, 2025, and then presented as a late-breaking abstract at the European Society for Medical Oncology (ESMO) Congress,1 the study's hand-picked performance metrics prompted a wave of enthusiastic, uncritical reporting across mainstream media outlets. 2025-12-22T23:30:01Z
[Articles] O-(2-[18F]fluoroethyl)-L-tyrosine-PET-guided versus contrast-enhanced T1-weighted MRI-guided re-irradiation in patients with recurrent glioblastoma (GLIAA/NOA-10 ARO2013-01): a multicentre, open-label, randomised trial FET-PET-based target volume delineation for re-irradiation did not lead to a significant clinical benefit compared with CE-T1MRI-based treatment in patients with recurrent glioblastoma. Thus, CE-T1MRI remains the preferred delineation method in this setting. 2025-12-19T23:30:01Z
[News] Progress in global tobacco control measures Global tobacco control measures have led to substantial decrease in the number of tobacco users—from 1·38 billion in 2000 to 1·20 billion in 2024, but there are concerns over possible undermining of these measures in some countries, due to untoward activities including illicit tobacco trade and interference of the tobacco industry in policy making. 2025-12-18T23:30:01Z
[News] San Antonio Breast Cancer Symposium 2025 In the phase 3 IidERA trial presented by Aditya Bardia (University of California Los Angeles, Los Angeles, CA, USA), adjuvant giredestrant, an oral selective oestrogen receptor degrader (SERD) showed significant improvement in invasive disease-free survival (iDFS) compared with standard-of-care endocrine therapy in patients with early-stage HR+ HER2– breast cancer. 4170 patients were randomly assigned (1:1) to receive either 30 mg of giredestrant or tamoxifen, letrozole, anastrozole, or exemestane. 2025-12-18T23:30:01Z
|
[Editorial] Lymphoma in the BiTE era
The development of bispecific antibodies to treat B-cell non-Hodgkin lymphoma has marked a substantial advance that offers new hope for patients. The bispecific T-cell engager epcoritamab joins a growing list of treatments for several lymphoma settings, with encouraging results presented at the American Society of Hematology (ASH) annual meeting. In the EPCORE FL-1 trial, 488 patients with relapsed or refractory follicular lymphoma received lenalidomide and rituximab with and without epcoritamab, with a positive result for the dual primary endpoint of overall response rate and progression-free survival leading to this combination being approved by the US Food and Drug Administration (FDA) on Nov 18, and it joins mosunetuzumab as a bispecific antibody treatment option for this disease setting. Thu, 01 Jan 2026 00:00:00 -0800
[Editorial] Thalassaemia: advocacy, resilience, and adaptability “The patient voice, especially when informed and reflective, can illuminate blind spots that data alone cannot,” writes Roanna Maharaj, a patient with β-thalassaemia, emphasising the importance of patients being active participants in decision making, and one of several articles on thalassaemia in this issue of The Lancet Haematology. That there are now multiple treatment options is a testament to the work that has gone into improving outcomes for patients in recent years and is also discussed in a Viewpoint that presents a prioritisation-based matrix for deciding how best to treat transfusion-dependent β-thalassaemia in settings with limited resources. Thu, 01 Jan 2026 00:00:00 -0800
[Corrections] Correction to Lancet Haematol 2025; 12: e978–85 Esther CHL, Fan BE, Hew YY, Poon LM. Medical tourism for cellular therapy: a clinical perspective. Lancet Haematol 2025; 12: e978–85—In this Viewpoint, Bingwen Eugene Fan's name was incorrect. This correction has been made to the online version as of Dec 31, 2025. Thu, 01 Jan 2026 00:00:00 -0800
[In Focus] Lessons from both sides of the bedrail I was 8 years old when my spleen nearly ruptured. The first sign was not pain but the sudden inability to finish dinner—dangerous ground in a Cypriot immigrant family. My mother rubbed warm olive oil on my abdomen, a home remedy that offered comfort but no cure. Days later we learned my spleen had grown so large it pressed against my stomach, making eating impossible. Despite days in hospital and a transfusion, my greatest relief was being absolved of the cardinal sin of leaving my mother's louví (black eyed peas) unfinished. Thu, 01 Jan 2026 00:00:00 -0800
[In Focus] Living between roles: navigating professional and patient identities with thalassaemia “Empathy begins where certainty ends.”
— Anonymous Thu, 01 Jan 2026 00:00:00 -0800
[In Focus] Thalassaemia clinical trials in war-stricken Lebanon: a story of struggle and resilience The conduct of thalassaemia-related clinical trials in Lebanon, a nation recently afflicted by armed conflict, reflects the exceptional resilience, ingenuity, and adaptability of its health-care professionals. Despite enduring an escalating threat of armed violence, clinical research in Lebanon has not only survived, but it has also evolved. This Global haematology article outlines how thalassaemia clinical trials were managed under wartime conditions at the Chronic Care Center, a specialised long-term care thalassaemia centre located in Hazmieh, Lebanon, and affiliated with the American University of Beirut in Lebanon. Thu, 01 Jan 2026 00:00:00 -0800
[Articles] Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b/2 trial In patients with Richter transformation, epcoritamab monotherapy showed clinically meaningful antitumour activity, although the investigator-assessed overall response rate was below the alternative hypothesis of 50%, with a safety profile consistent with previous studies. These findings support further investigation of epcoritamab as a potential treatment option for patients with Richter transformation. Mon, 08 Dec 2025 21:30:02 +0000
[Articles] Intravenous iron for non-anaemic iron deficiency in pregnancy: a multicentre, two-arm, randomised controlled trial Among non-anaemic iron deficient pregnant women, intravenous iron therapy significantly improved maternal haemoglobin before delivery, compared with oral iron prophylaxis. Ferritin screening should be considered in early pregnancy, as intravenous iron therapy is effective in those tested positive for non-anaemic deficiency. Thu, 01 Jan 2026 00:00:00 -0800
[Articles] Iberdomide plus low-dose cyclophosphamide and dexamethasone in patients with relapsed and refractory multiple myeloma (the ICON study): a multicentre, single-arm, phase 2 trial IberCd is an all-oral and active combination for patients with relapsed and refractory multiple myeloma that showed clinically meaningful activity. This regimen offers a valuable treatment option for patients who have received two to four previous lines of therapy and compares favourably with other available treatments. Thu, 01 Jan 2026 00:00:00 -0800
[Articles] Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial During extended treatment for cancer-associated VTE, four predictors of clinically relevant bleeding were identified in the overall population, with no evidence of interaction with the dosing regimen. Although the API-CAT study was not designed to specifically address anticoagulation discontinuation, our findings might help clinicians to more effectively balance the benefits and risks of extended anticoagulant therapy. Sat, 06 Dec 2025 08:00:01 +0000
[Viewpoint] Management of transfusion-dependent β-thalassaemia in the era of novel therapies: a prioritisation-based matrix for settings with limited resources β-thalassaemia is an inherited haemoglobinopathy characterised by ineffective erythropoiesis and chronic anaemia of varying severity, which is predominant in the region extending from the Mediterranean basin and Middle East towards southeast Asia. Patients with severe phenotypes require lifelong transfusions, iron overload monitoring, and chelation. Suboptimal management due to access challenges continues to be directly linked to increased morbidity and mortality in many regions. In the past few decades, an improved understanding of the underlying pathogenesis of β-thalassaemia has led to the development of several disease-modifying therapies and curative gene manipulation techniques. Thu, 01 Jan 2026 00:00:00 -0800
|
|
| ||
|
A small step yet one giant leap for cGVHD biomarkers
Volume 147, Issue 3 January 15 2026 Patient-reported outcomes: a Polaris for POLARIX Volume 147, Issue 3 January 15 2026 Time to say adieu to FISH in myeloma diagnostics Volume 147, Issue 3 January 15 2026 Resistance is not futile: RAS inhibition resensitizes AML Volume 147, Issue 3 January 15 2026 Duffy-null reference ranges for improved clinical care Volume 147, Issue 3 January 15 2026 miR-aculous effects for hemophilic arthropathy Volume 147, Issue 3 January 15 2026 CPX-351 in Down syndrome–associated myeloid leukemia: results and prognostic factors from the phase 3 ML-DS 2018 trial Volume 147, Issue 3 January 15 2026 Distinct biological subtypes of chronic GVHD after pediatric hematopoietic cell transplantation Chronic graft-versus-host disease (cGVHD) is a biologically complex and heterogeneous disorder driven by immune dysregulation that results in fibrotic end-organ damage, yet it has been considered a single entity. Ng et al used clustering analyses of a large pediatric cohort from the Applied Biomarkers of Late Effects of Childhood Cancer (ABLE) network to delineate 3 biologically distinct cGVHD subtypes defined by unique immune and metabolomic signatures. This work provides an important first step toward biomarker-guided stratification and individualized therapy, while recognizing the need for prospective validation and clinically feasible assays.
Volume 147, Issue 3 January 15 2026 PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study In the phase 3 POLARIX study, patients with previously untreated diffuse large B cell lymphoma (DLBCL) who were treated with Pola-R-CHP (polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone) had superior progression-free survival compared to those treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Thompson et al evaluated patient-reported outcome (PRO) instruments in the POLARIX study and noted that both treatments result in rapid, clinically meaningful, and durable improvements in lymphoma symptoms and health-related quality of life. Of note, comparison between PROs and clinician-reported adverse events revealed a notable discordance, with symptoms of fatigue, nausea, and vomiting having higher incidence according to PROs, emphasizing the value of including these instruments to more completely capture the patient experience.
Volume 147, Issue 3 January 15 2026 High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing The International Myeloma Society and International Myeloma Working Group have proposed a revised high-risk (HR) genomic model called Consensus Genomic Staging (CGS). Schavgoulidze et al evaluated this model on a large cohort of patients with newly diagnosed multiple myeloma and validated the CGS definition of high-risk multiple myeloma. This study provides strong evidence supporting the adoption of next-generation sequencing strategies to improve risk stratification in newly diagnosed myeloma.
Volume 147, Issue 3 January 15 2026 Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML Aberrant activation of RAS/MAPK signaling limits the clinical efficacy of several targeted therapies for acute myeloid leukemia (AML). Popescu et al show that a novel multiselective RAS(ON) inhibitor, RMC-7977, resensitizes previously resistant cell lines and primary AML specimens to FLT3 and BCL2 inhibition. These results provide a strong rationale for clinical testing of this strategy for FLT3 inhibitor– and/or BCL2 inhibitor–resistant AML with RAS mutation.
Volume 147, Issue 3 January 15 2026 Multinational assessment of absolute neutrophil counts and white blood cell counts among healthy Duffy-null adults The Duffy-null variant lowers absolute neutrophil counts (ANCs), but existing dedicated reference intervals are based on a single African American cohort. Hibbs et al established and compared healthy adult Duffy-null ANC and white blood cell (WBC) reference intervals across 4 continents and found that Duffy-null individuals consistently exhibit lower ANCs and WBC counts across ethnic groups and regions. This analysis supports implementation of Duffy-null–specific reference ranges as a feasible, impactful step for clinical laboratories to reduce health care inequities.
Volume 147, Issue 3 January 15 2026 Factor VIIa–released extracellular vesicles attenuate joint bleed–induced hemophilic arthropathy Contemporary therapies for hemophilia do not always prevent the development of hemophilic arthropathy (HA), prompting efforts to identify strategies to mitigate joint damage after bleeding episodes. Kavadipula et al report that administration of factor VIIa–released endothelial extracellular vesicles (eEVs) markedly suppresses joint bleed–induced synovial inflammation and prevents the development of HA in a murine model of hemophilia. Mechanistically, miR10a contained within eEVs is the key mediator of this protective effect, suggesting that miR10a-based approaches may be a therapeutic strategy for preventing hemophilic arthropathy.
Volume 147, Issue 3 January 15 2026 Prior transplantation and idecabtagene vicleucel in multiple myeloma: a secondary analysis of CIBMTR data Volume 147, Issue 3 January 15 2026 Elevated serum erythropoietin level in JAK2+ polycythemia vera with small vessel Budd-Chiari syndrome Volume 147, Issue 3 January 15 2026 ML-DS 2018 TRIAL Volume 147, Issue 3 January 15 2026 Volume 147, Issue 3 January 15 2026 |
Prevalence of Iron Deficiency and Iron Deficiency Anemia in US Pregnant Individuals, 2003–2023
Thu, 15 Jan 2026 22:00:35 -0800 Patients First: Navigating Asparaginase‐Based Treatment in Young Adults With Acute Lymphoblastic Leukemia Wed, 14 Jan 2026 02:31:15 -0800 A Murine Bispecific Antibody Efficiently Redirects T Cells Against Calr Mutated Stem Cells In Vivo Wed, 14 Jan 2026 01:18:26 -0800 Trends in Smoldering Myeloma Incidence in the United States From Cancer Registries, 2012–2022 Tue, 13 Jan 2026 04:50:30 -0800 RBC Alloimmunization Impacts Pediatric Sickle Cell Disease Transplant Outcomes and Transfusion Burden: A STAR Registry Report Mon, 12 Jan 2026 06:52:53 -0800 Idiopathic Multicentric Castleman Disease—TAFRO: A Potentially Curable Disease? Sat, 10 Jan 2026 02:54:47 -0800 Rare and Deadly Complication of Disseminated Toxoplasma gondii Infection After Allogeneic Hematopoietic Stem Cell Transplantation: Hemophagocytic Lymphohistiocytosis Fri, 09 Jan 2026 04:37:11 -0800 Chimeric Antigen Receptor T‐Cells (CAR T‐Cells) in Hematological Malignancies: A Systematic Review and Meta‐Analysis of Proportions From Clinical Trials Fri, 09 Jan 2026 04:00:36 -0800 Long‐Term Outcomes of Stem Cell Transplant in Older Patients With Acute Myeloid Leukemia Treated With Venetoclax‐Based Therapies Fri, 09 Jan 2026 02:09:22 -0800 Clonal Hematopoiesis of Indeterminate Potential and Clonal Cytopenias of Undetermined Significance: 2026 Update on Clinical Associations and Management Recommendations Thu, 08 Jan 2026 22:40:24 -0800 Post‐FDA Approval Experience With Momelotinib in JAK Inhibitor‐Naïve Myelofibrosis: Focus on Anemia Response and Treatment‐Emergent Nephropathy and Peripheral Neuropathy Thu, 08 Jan 2026 04:16:20 -0800 Real‐World Effectiveness and Safety of Fostamatinib in Difficult‐to‐Treat Immune Thrombocytopenia Patients. A Prospective, Multicenter Registry in France Thu, 08 Jan 2026 04:15:07 -0800 Mechanistic Consequences of Piezo1 Gain‐of‐Function Variants for Decreased Red Cell Survival in Hereditary Xerocytosis Thu, 08 Jan 2026 04:04:52 -0800 Incidence, Characteristics, and Management of Venous Thrombosis in Adult Patients With Immune Thrombocytopenia: Results From the Multicenter, Prospective Registry CARMEN‐France Thu, 08 Jan 2026 03:41:30 -0800 Iron Overload and Anemia in Transferrin Immune Complex Disease, an Overlooked Monoclonal Gammopathy of Clinical Significance Wed, 07 Jan 2026 05:34:44 -0800 Hematologic Landscape of Adult Patients With Diamond‐Blackfan Anemia Syndrome Wed, 07 Jan 2026 05:21:25 -0800 Impact of Optimizing the Lower Limit of Normal for Ferritin on Iron Deficiency Diagnosis and Treatment Patterns: A Pre and Post‐Intervention Study Using EHR Data Tue, 06 Jan 2026 03:45:02 -0800 Preoperative Iron Status and the Risk of Severe Postoperative Anemia After Metabolic and Bariatric Surgery Tue, 06 Jan 2026 03:27:21 -0800 Serum H‐Ferritin‐To‐Ferritin Ratio as a Biomarker of Hemophagocytic Lymphohistiocytosis in Critically Ill Patients With Hyperferritinemia Tue, 06 Jan 2026 03:01:41 -0800 Effect of Red Blood Cell Transfusion on Inflammatory and Angiogenic Pathways in Patients With Sickle Cell Disease Tue, 06 Jan 2026 00:00:00 -0800 Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction Therapy Mon, 05 Jan 2026 23:07:00 -0800 |
Issue Information
January 2026 Diverse career paths within thrombosis and hemostasis: perspectives from the ISTH early career committee October 22, 2025 Treating von Willebrand disease without von Willebrand factor January 2026 Mouse trials and human triumphs: recovery after hemarthrosis? January 2026 Thrombosis magnified—zooming in to get to the bottom of clot formation January 2026 Reducing the risk of venous thromboembolism in pregnant women with inherited antithrombin deficiency January 2026 Venous ultrasonography and computed tomography venography in diagnosis of peripherally inserted central venous catheter–associated venous thrombosis: complementary strategies for expecting the unexpected? January 2026 Modulating platelet checkpoints: from storage lesion to thrombo-inflammation January 2026 Redefining emperipolesis: a controlled mechanism of megakaryocyte function January 2026 A novel homozygous splice-site variant in VPS33B identified as a cause of bleeding October 23, 2025 Concizumab use in toddlers with hemophilia B and inhibitors real-world data from an international collaboration October 23, 2025 Knowledge, interest, and willingness of hematologists and oncologists to care for adults with vascular anomalies October 23, 2025 Shapes and dimensions of blood clots affect the rate and extent of platelet-driven clot contraction and determine the outcomes of thrombosis December 17, 2025 Impact of hospital-acquired venous thromboembolism on surviving a medical admission: findings from the Medical Inpatient Thrombosis and Hemostasis Study October 22, 2025 “Safe and effective anticoagulation use: case studies in anticoagulation stewardship”: comment January 2026 “Safe and effective anticoagulation use: case studies in anticoagulation stewardship”: reply January 2026 “Thromboembolism in transplant-ineligible multiple myeloma patients on triplet/quadruplet therapy: a post hoc analysis of BENEFIT”: comment from Galarza Fortuna et al. January 2026 |
|
| ||
|
MRD assessment by flow cytometry in B-ALL made easier January 13 2026 - Volume 10, Issue 1 Targeting the lectin pathway in TA-TMA January 13 2026 - Volume 10, Issue 1 Give megs a break: minor DNA stress, platelets in excess January 13 2026 - Volume 10, Issue 1 AI-generated peptides for research and clinical practice January 13 2026 - Volume 10, Issue 1 More than CLK bait? Rogocekib for MDS and AML January 13 2026 - Volume 10, Issue 1 Blood tests to predict CAR T-cell toxicity and efficacy January 13 2026 - Volume 10, Issue 1 The ASH Research Collaborative Sickle Cell Disease Research Network: past, present, and future January 13 2026 - Volume 10, Issue 1 BK virus kinetics and associated cystitis/urethritis symptoms after PTCy-based allogeneic hematopoietic cell transplant January 13 2026 - Volume 10, Issue 1 Safety and efficacy of daratumumab in immune thrombocytopenia January 13 2026 - Volume 10, Issue 1 Risk biomarkers of chronic GVHD in children aged 10 years or younger and children/adults older than 10 years January 13 2026 - Volume 10, Issue 1 Phase 1 study of rogocekib in patients with relapsed or refractory hematologic malignancies January 13 2026 - Volume 10, Issue 1 Accelerating novel therapies for sickle cell disease with RWE: ASH RC Data Hub as a strategically coordinated registry network January 13 2026 - Volume 10, Issue 1 Tumor-specific immune responses and biomarkers in pediatric patients with high-risk Hodgkin lymphoma January 13 2026 - Volume 10, Issue 1 Tumor microenvironment differences between diagnostic and relapsed classic Hodgkin lymphoma revealed by scRNA-seq January 13 2026 - Volume 10, Issue 1 Artificial intelligence accelerates the interpretation of measurable residual B lymphoblastic leukemia by flow cytometry January 13 2026 - Volume 10, Issue 1 Outcome of patients with mantle cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T study by LYSA Group January 13 2026 - Volume 10, Issue 1 New comorbidity index associated with survival after chimeric antigen receptor T-cell therapy for large B-cell lymphoma January 13 2026 - Volume 10, Issue 1 CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia January 13 2026 - Volume 10, Issue 1 Diagnostic sequencing identifies high-risk markers and mechanisms of resistance to guide immunotherapy selection January 13 2026 - Volume 10, Issue 1 MicroRNA-223-3p is a determinant of platelet procoagulant activity January 13 2026 - Volume 10, Issue 1 Induction of moderate DNA damage enhances megakaryopoiesis and platelet production January 13 2026 - Volume 10, Issue 1 Effect of obexelimab on the production of anti-RBC antibodies and cytokines in patients with warm autoimmune hemolytic anemia January 13 2026 - Volume 10, Issue 1 Comparison of anticoagulants and risk of ischemic stroke in patients with acute cancer-associated venous thromboembolism January 13 2026 - Volume 10, Issue 1 Pyruvate kinase M2 promotes venous thrombosis by enhancing SNAP23-mediated platelet exocytosis and consequent NETosis January 13 2026 - Volume 10, Issue 1 Developing an artificial intelligence–generated peptide targeting platelet-type von Willebrand disease January 13 2026 - Volume 10, Issue 1 Short- and long-term effects of transfusion in β-thalassemia: a longitudinal study of transfusion efficiency factors January 13 2026 - Volume 10, Issue 1 Survival in adults with high-risk TA-TMA: a comparative analysis of narsoplimab vs supportive care January 13 2026 - Volume 10, Issue 1 Matched unrelated vs haploidentical donor hematopoietic cell transplantation using posttransplant cyclophosphamide January 13 2026 - Volume 10, Issue 1 Mini-hyper-CVD plus venetoclax and navitoclax for relapsed/refractory acute lymphoblastic leukemia January 13 2026 - Volume 10, Issue 1 Age-based pegaspargase dosing is safe and achieves therapeutic levels in infants with ALL: report from COG AALL15P1 January 13 2026 - Volume 10, Issue 1 Liberalizing hospital proximity requirements for children/young adults with low-burden B-ALL receiving tisagenlecleucel January 13 2026 - Volume 10, Issue 1 Danazol treatment for telomere biology disorders: long-term results of a phase 1/2 study January 13 2026 - Volume 10, Issue 1 Outcomes of bispecific antibodies after CAR T-cell failure for large B-cell lymphoma: results from the ABC consortium January 13 2026 - Volume 10, Issue 1 Casulo C, Dixon JG, Ou F-S, et al. Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials. Blood Adv. 2021;5(6):1737-1745. January 13 2026 - Volume 10, Issue 1 Chihara D, Steiner RE, Nair R, et al. Phase 2 trial of ibrutinib and nivolumab in patients with relapsed CNS lymphomas. Blood Adv. 2025;9(7):1485-1491. January 13 2026 - Volume 10, Issue 1 |
American Society of Hematology/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients Blood Adv (2025) 9 (10): 2587–2636. ASH Clinical Practice Guidelines: strategies to stay up-to-date Blood Adv (2023) 7 (21): 6707–6709. American Society of Hematology, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panamena de Hematología, Sociedad Peruana de Hematología, and SVH 2023 guidelines for diagnosis of venous thromboembolism and for its management in special populations in Latin America Blood Adv (2023) 7 (13): 3005–3021. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients Blood Adv (2022) 6 (17): 4975–4982. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients Blood Adv (2022) 6 (17): 4915–4923. American Society of Hematology, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, Sociedad Peruana de Hematología, and SVH 2022 guidelines for prevention of venous thromboembolism in surgical and medical patients and long-distance travelers in Latin America Blood Adv (2022) 6 (12): 3636–3649. The ASH-ASPHO Choosing Wisely Campaign: 5 hematologic tests and treatments to question Blood Adv (2022) 6 (2): 679–685. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis Blood Adv (2022) 6 (2): 664–671. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients Blood Adv (2021) 5 (20): 3951–3959. American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation Blood Adv (2021) 5 (18): 3668–3689. ASH, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, SPH, and SVH 2021 guidelines for management of venous thromboembolism in Latin America Blood Adv (2021) 5 (15): 3032–3046. Methodology for adaptation of the ASH Guidelines for Management of Venous Thromboembolism for the Latin American context Blood Adv (2021) 5 (15): 3047–3052. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer Blood Adv (2021) 5 (4): 927–974. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19 Blood Adv (2021) 5 (3): 872–888. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease Blood Adv (2021) 5 (1): 301–325. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease Blood Adv (2021) 5 (1): 280–300. American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults Blood Adv (2020) 4 (15): 3528–3549. American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain Blood Adv (2020) 4 (12): 2656–2701. Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences Blood Adv (2020) 4 (10): 2351–2365. |
|
|
| ||
|
|
Dynamic signature for the effectiveness of anti–PD‐1 therapy combined with vascular normalization therapy in recurrent glioblastoma: A randomized phase 2 trial
Wed, 14 Jan 2026 08:15:23 -0800 A pilot study of chemoimmunotherapy in the postconsolidation setting for high‐risk neuroblastoma (ANBL19P1): A report from the Children’s Oncology Group The administration of chemoimmunotherapy in the postconsolidation setting after tandem ASCT is feasible and tolerable. Future studies will be needed to define the population most likely to benefit from this augmented postconsolidation therapy. Mon, 12 Jan 2026 21:59:47 -0800 Sex differences in the clinical presentation of patients with newly diagnosed multiple myeloma Mon, 12 Jan 2026 00:01:06 -0800 Integration of food and nutrition into oncology care: Proceedings of the Food is Medicine in Oncology Care Symposium Fri, 09 Jan 2026 08:50:15 -0800 Issue Information Wed, 07 Jan 2026 08:20:55 -0800 Exercise recommendations for older adults living with and beyond cancer: A consensus statement by the Advancing Capacity to Integrate Exercise Into the Care of Older Cancer Survivors expert panel Older cancer survivors can benefit from appropriately prescribed exercise, which should be an essential component of their cancer care. Exercise and health professionals need to consider the unique needs of older cancer survivors to ensure that exercise is safe and effective for this population, while also reducing barriers to reach as many people as possible. Wed, 07 Jan 2026 00:00:00 -0800 |
|
|
| ||
|
|
|
|
|
| ||
|
Triplet Therapy Demonstrates Superior Progression-Free Survival in First-Line dMMR/MSI-H Metastatic Colorectal Cancer
The combination regimen of FOLFOX chemotherapy (leucovorin, fluorouracil, and oxaliplatin), bevacizumab, and atezolizumab led to a statistically significant improvement in progression-free survival compared with atezolizumab monotherapy for the first-line treatment of patients with deficient... Tuesday, January 6, 2026 10:30 AM Can Multimodal AI Models Predict Distant Recurrence Risk in Patients With Early Breast Cancer? Multimodal artificial intelligence (AI) models using a combination of molecular, imaging, and clinical features improved the individual prognostic assessment of patients with early breast cancer's risk of distant recurrence, according to an analysis presented at the 2025 San Antonio Breast Cancer... Friday, December 12, 2025 2:45 PM HER2-Positive Gastroesophageal Cancer: Zanidatamab Plus Chemotherapy Prolongs Progression-Free Survival Results from a new phase III study showed that in patients with HER2-positive metastatic gastroesophageal adenocarcinoma, the combination of the dual HER2-targeted bispecific antibody zanidatamab and chemotherapy, with or without the PD-1 inhibitor tislelizumab, extended progression-free survival.... Tuesday, January 6, 2026 3:32 PM Improved Contralateral Breast Cancer Risk Knowledge With Personalized Counseling Tool Patients with unilateral breast cancer who underwent quantitative counseling with a personalized tool incorporating genetic testing results were better informed of their contralateral breast cancer risk compared with those who received standard counseling, according to results from the GET FACTS... Machine Learning–Guided ‘Optical Biopsy’ Accurately Identifies Malignant Lung Nodules Intraoperatively In a cohort study reported in JAMA Network Open, Azari et al evaluated whether machine learning–guided analysis of intraoperative molecular imaging (IMI) data could accurately and rapidly determine the malignant potential of indeterminate lung nodules during surgery. The study was undertaken to... Genetic Predisposition to Higher Body Mass Index Linked to Mortality After Breast Cancer In an observational cohort study published in JAMA Network Open, Bodelon et al examined whether inherited susceptibility to excess body weight influences long-term survival among breast cancer survivors. Using a polygenic score for body mass index (BMI), the investigators sought to determine... Machine Learning Approach Accelerates Discovery of Novel CDK9 Inhibitors A virtual screening campaign using machine learning identified molecules with potential for development as novel CDK9 inhibitors for the treatment of cancer, according to early research findings published in Biomolecules. Integration of artificial intelligence (AI) into the drug discovery phase... Thursday, January 15, 2026 9:30 AM SCLC: Small Study Tests Efficacy of CTCs in Predicting Response to Tarlatamab A research team has discovered that a particular marker on circulating tumor cells (CTCs) may indicate whether a patient with small cell lung cancer (SCLC) will experience a lasting response to tarlatamab-dlle, a newly approved immunotherapy. The findings, which were published by Mishra in Cancer... Thursday, January 15, 2026 10:03 AM ACS Report Shows 5-Year Survival Rate for All Cancers Combined Has Reached 70% New data published by Siegel et al in the American Cancer Society’s (ACS) Cancer Statistics, 2026 report show that, for the first time, the 5-year survival rate for all cancers combined has reached 70% for individuals diagnosed during 2015 to 2021 in the United States. In addition, those diagnosed... Breast Cancer Recurrence Risk Determined by Deep Learning Model Trained on Histopathologic Slides A deep learning model demonstrated the ability to predict breast cancer recurrence risk and possible benefit from the addition of chemotherapy based on histopathologic images rather than genomic testing in patients with hormone receptor–positive, HER2-negative breast cancer, according to findings... Novel Endocrine Therapy, Giredestrant, Improves Invasive Disease–Free Survival in Estrogen Receptor–Positive, HER2-Negative Early Breast Cancer Nivolumab Plus AVD Reduces Disease Progression Risk in Adolescents With Advanced Classical Hodgkin Lymphoma A combination of nivolumab with AVD chemotherapy (doxorubicin, vinblastine, and dacarbazine) demonstrated a significant reduction in the risk of disease progression or death compared with brentuximab vedotin plus AVD in adolescent patients with newly diagnosed advanced classical Hodgkin lymphoma,... Wednesday, January 14, 2026 12:00 PM Whole-Genome Sequencing–Based Classifier Better Predicts Homologous Recombination Deficiency Across Cancer Types A whole-genome sequencing–based classifier demonstrated greater performance for predicting homologous recombination deficiency (HRD) across cancer types than standard assays, which in turn determined which patients with cancer would benefit from treatment with PARP inhibitors, according to findings ... Wednesday, January 14, 2026 10:30 AM Can DNA Testing of Colorectal Polyps Improve Insight Into Genetic Risks? It is estimated that hereditary factors play a role in about 5% to 10% of colorectal cancer cases, with a higher prevalence of hereditary factors seen in younger patients. Many colorectal polyps are considered potential precursors to cancer: at least 10 polyps in individuals younger than 60 years... Wednesday, January 14, 2026 9:00 AM Pirtobrutinib vs Ibrutinib in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma In a phase III trial (BRUIN CLL-314) reported in the Journal of Clinical Oncology, Woyach et al found that pirtobrutinib was associated with a noninferior objective response rate vs ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, while also being associated with... Multiple Myeloma: Sex Differences in Etiology and Clinical Presentation Rates of multiple myeloma, the second most common blood cancer in the United States, are increasing and are twice as high in men than in women. A new study published by Ong et al in the journal Cancer provides insights that may help to explain this disparity. Tuesday, January 13, 2026 1:49 PM Addition of Nivolumab to Docetaxel in ARPI-Pretreated, Chemotherapy-Naive Advanced Prostate Cancer As reported in The Lancet Oncology by Fizazi et al, the phase III CheckMate 7DX trial showed no progression-free or overall survival benefit with the addition of nivolumab to docetaxel in patients with androgen receptor pathway inhibitor (ARPI)–pretreated and chemotherapy-naive metastatic... Addition of Postoperative Nivolumab to Cisplatin and Radiotherapy in High-Risk Locally Advanced HNSCC In a phase III trial (GORTEC 2018-01, NIVOPOST-OP) reported in The Lancet, Bourhis et al found that the addition of adjuvant nivolumab to cisplatin and radiotherapy improved disease-free survival in patients with high-risk, resected, locally advanced squamous cell carcinoma of the head and neck... MajesTEC-3: ‘Unprecedented’ Benefit in Previously Treated Multiple Myeloma For patients with previously treated multiple myeloma, the greatest risk reduction yet achieved in a phase III clinical trial was reported with the BCMA-directed CD3 T-cell engager teclistamab-cqyv plus daratumumab and hyaluronidase-fihj. Treatment with this combination resulted in an 83% reduction ... Do GLP-1 RAs Reduce the Risk of Developing Colorectal Cancer More Than Aspirin? Excluding skin cancers, colorectal cancer is the third most common cancer diagnosed in both men and women in the United States. According to the American Cancer Society, in 2025, about 154,270 individuals were diagnosed with colorectal cancer, and approximately 53,000 individuals died from the... High Neighborhood Fast Food Expenditure and Early-Onset Colorectal Cancer Studies show that while the overall rates of colorectal cancer are decreasing, for individuals younger than age 50, the incidence has risen by an alarming 50% since the mid-1990s. While the exact causes are unknown, poor diet and alcohol consumption are believed to be contributing factors. A study... In Head-to-Head Comparison, Fixed-Duration Treatment Noninferior to Continuous for Previously Untreated CLL Based on the phase III CLL17 trial, a fixed duration of targeted treatment demonstrated noninferiority to continuous treatment with respect to progression-free survival in previously untreated patients with chronic lymphocytic leukemia (CLL). The findings were presented at the Plenary Session of... Can KDM6A Mutations Help Guide Treatment Selection in Bladder Cancer? Mutations in KDM6A have been identified as a regulator of therapeutic responses in advanced bladder cancer, sensitizing tumors to anti–PD-1 immune checkpoint inhibition but resisting cisplatin chemotherapy, according to early research published in Nature Communications. Based on this and further... Monday, January 12, 2026 10:15 AM Anaplastic Glioma: Concurrent vs Adjuvant Temozolomide As reported in The Lancet Oncology by van den Bent et al, the final analysis of the phase III CATNON trial has shown continued overall survival benefit with radiotherapy followed by 12 cycles of adjuvant temozolomide in patients with newly diagnosed 1p/19q non–co-deleted anaplastic gliomas;... Molecular Profile–Based Adjuvant Treatment in High-Intermediate Risk Endometrial Cancer In a European phase III trial (PORTEC-4a) reported in The Lancet Oncology, van den Heerik et al found that molecular profile–based adjuvant treatment produced favorable results in women with high-intermediate risk endometrial cancer and allowed patients with favorable risk to be spared adjuvant... Refractory LBCL: CD19-Targeting CAR T-Cell Therapy Plus Rituximab A dual-antigen targeting combination of the CD19-targeting chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel plus the CD20-targeting agent rituximab led to durable responses and reduced relapses in patients with refractory large B-cell lymphoma (LBCL), according to findings... Monday, January 12, 2026 10:30 AM |
Sex-related differences in dynamic right ventricular-pulmonary vascular coupling in heart failure with preserved ejection fraction Right ventricle (RV) dysfunction is associated with poorer outcomes in heart failure with preserved ejection fraction (HFpEF). Females are more likely to have HFpEF but males have worse prognosis and resting RV function. The contribution of dynamic RV-pulmonary artery (RV-PA) coupling between sex and its impact on peak exercise capacity (VO2) in HFpEF is not known. Thu, 31 Dec 2020 20:15:06 -0800 Phase II Investigation of the efficacy of Antimycobacterial therapy in Chronic Pulmonary Sarcoidosis A Phase I, single-center investigation demonstrated that 8 weeks of antimycobacterial therapy improved sarcoidosis forced vital capacity (FVC). Safety and efficacy assessments have not been performed in a multicenter cohort. Wed, 30 Dec 2020 20:15:06 -0800 Medical Education During the COVID-19 Pandemic All aspects of medical education were affected by the Novel Coronavirus Infectious Disease-19 (COVID-19) pandemic. Several challenges were experienced by trainees and programs alike due to the economic repercussions of the pandemic, how social distancing affected the delivery of medical education, testing and interviewing, how the surge of patients affected redeployment of personnel, potential compromise in core training and the overall impact on the wellness and mental health of trainees and educators. Tue, 29 Dec 2020 20:15:06 -0800 Impact of Bronchiectasis on incident NTM pulmonary disease: A 10-Year national cohort study Sat, 26 Dec 2020 20:15:06 -0800 Categorized Priority Systems: A New Tool for Fairly Allocating Scarce Medical Resources in the Face of Profound Social Inequities Fri, 25 Dec 2020 20:15:06 -0800 Impact of Right Ventricular Dysfunction on Short- and Long-Term Mortality in Sepsis: A Meta-Analysis of 1,373 Patients In this meta-analysis of observational studies, RV dysfunction was associated with higher short-term and long-term mortality in sepsis and septic shock. Wed, 23 Dec 2020 20:15:06 -0800 RESEARCH LETTER: Pulmonary function and risk of Alzheimer dementia: two-sample Mendelian randomization study Mon, 21 Dec 2020 20:15:06 -0800 “We usually don’t vote on intubation.” Mon, 21 Dec 2020 20:15:06 -0800 Risk factors, management, and outcomes of legionella pneumonia in a large nationally-representative sample Legionella is an uncommon cause of CAP, occurring primarily from late spring through early autumn. Testing is uncommon, even among patients with risk factors, and many positive patients failed to receive empiric coverage for LP. Sat, 19 Dec 2020 20:15:06 -0800 Which N descriptor is more predictive of prognosis in resected non-small cell lung cancer: the number of involved nodal stations versus the location-based pathological N stage? The nS classification could be used to provide a more accurate prognosis in patients with resected NSCLC. The nS is worth taking into consideration when defining nodal category in the forthcoming ninth edition of the staging system. Sat, 19 Dec 2020 20:15:06 -0800 Identifying and characterizing a chronic cough cohort through electronic health records NLP successfully identified a large cohort with CC. Most patients were identified through NLP alone, rather than diagnoses or medications. NLP improved detection of patients nearly seven-fold, addressing the gap in ability to identify and characterize CC disease burden. Nearly all cases appeared to be managed in primary care. Identifying these patients is important for characterizing treatment and unmet needs. Thu, 17 Dec 2020 20:15:06 -0800 Development and validation of algorithms to identify pulmonary arterial hypertension in administrative data Pulmonary arterial hypertension (PAH) is a rare disease and much of our understanding stems from single-center studies, which are limited by sample size and generalizability. Administrative data offer an appealing opportunity to inform clinical, research, and quality improvement efforts for PAH. Yet, there is currently no standardized, validated method to distinguish PAH from other subgroups of pulmonary hypertension (PH) within this data source. Thu, 17 Dec 2020 20:15:06 -0800 Development and Prospective Validation of a Deep Learning Algorithm for Predicting Need for Mechanical Ventilation A transparent DL algorithm improves on traditional clinical criteria to predict the need for MV in hospitalized patients, including in those with COVID-19. Such an algorithm may help clinicians optimize timing of tracheal intubation, better allocate resources and staff, and improve patient care. Thu, 17 Dec 2020 20:15:06 -0800 The clinical use of lung MRI in cystic fibrosis: what, now, how? To assess airway and lung parenchymal damage non-invasively in cystic fibrosis (CF), chest MRI has been historically out of the scope of routine clinical imaging due to technical difficulties such as the low proton density and respiratory and cardiac motion. However, technological breakthroughs have recently emerged to dramatically improve lung MRI quality (including signal-to-noise ratio, resolution, speed, contrast). At the same time, novel treatments have changed the landscape of CF clinical care. Thu, 17 Dec 2020 20:15:06 -0800 Endobronchial Valves for the Treatment of Advanced Emphysema Bronchoscopic lung volume reduction with one-way endobronchial valves is a guideline treatment option for patients with advanced emphysema, supported by extensive scientific data. Patients limited by severe hyperinflation, with a suitable emphysema treatment target lobe and with absence of collateral ventilation are the responders to this treatment. Detailed patient selection, a professional treatment performance, and dedicated follow-up of the valve treatment, including management of complications, are key ingredients to success. Thu, 17 Dec 2020 20:15:06 -0800 “How I Do It: Nurse Coordinator Roles and Responsibilities for Bronchoscopic Lung Volume Reduction with Endobronchial Valves” Chronic Obstructive Pulmonary Disease (COPD) may cause profound dyspnea, functional impairment, and reduced quality of life. Available pharmacologic therapy provides suboptimal symptom improvement in many patients. Bronchoscopic lung volume reduction (BLVR), achieved with endobronchial valve (EBV) placement, can effectively improve dyspnea and functional status in appropriately selected patients. Operationalizing a safe and effective BLVR program requires appropriate oversight which can be achieved by a BLVR Nurse Coordinator (NC). Tue, 15 Dec 2020 20:15:06 -0800 Oncology Care Provider (OCP) Training in Empathic Communication Skills to Reduce Lung Cancer Stigma Empathy-based, stigma-reducing communication may lead to improved assessments of tobacco use and smoking cessation for patients with smoking-related cancers. These findings support the dissemination and further testing of a new ECS model for training OCPs in best practices for assessment of smoking history and engagement of patients who currently smoke in tobacco treatment delivery. Tue, 15 Dec 2020 20:15:06 -0800 Clinical outcomes and healthcare resource utilization associated with reslizumab treatment in adults with severe eosinophilic asthma in real-world practice In clinical practice, reslizumab may have been initiated in response to heavy symptom burden and CAEs. Reslizumab was associated with improved clinical and patient-reported outcomes and significant reductions in asthma-related HRU. Mon, 14 Dec 2020 20:15:06 -0800 Decreasing case-fatality but not mortality rate following admission to intensive care units in Australia, 2005-2018. Mon, 14 Dec 2020 20:15:06 -0800 Quantitative Emphysema on Low-Dose Computed Tomography of the Chest and Risk of Lung Cancer and Airflow Obstruction: An analysis of the National Lung Screening Trial Quantitative emphysema measured on LDCT of the chest can be leveraged to improve lung cancer risk prediction and help diagnose COPD in individuals who currently or formerly smoked undergoing lung cancer screening. Mon, 14 Dec 2020 20:15:06 -0800 |
MicroRNAs in oncology: a translational perspective in the era of AI
Despite well-established roles of microRNAs (miRNAs) as tumour suppressors or oncogenes, miRNA-based diagnostics, prognostic tools and treatments have yet to be incorporated into routine oncology practice. In this Review, the authors discuss innovative approaches to address challenges in the clinical translation of miRNA-based diagnostics and treatments by integrating fundamental miRNA biology, multiomics and artificial intelligence-driven analyses. Thu, 15 Jan 2026 00:00:00 -0800 A guide to cancer screening Cancer screening aims to identify either pre-malignant conditions or earlier-stage disease in non-symptomatic individuals. The authors of this Review recapitulate the general principles of cancer screening, discussing the current screening practices for several cancer types as well as advances in cancer detection that might hold promise for screening an increasing number of cancers in the future. Wed, 07 Jan 2026 00:00:00 -0800 Base-edited CAR7 T cells are safe and efficacious in R/R T-ALL Base-edited CAR7 T cells are safe and efficacious in R/R T-ALL Tue, 06 Jan 2026 00:00:00 -0800 Discovery of predictive biomarkers for cancer therapy through computational approaches Treatment selection based on the presence of one or more specific biomarkers has the potential to optimize treatment outcomes; nonetheless, most patients lack a specific biomarker that is predictive of benefit from one or more targeted treatment approaches. In this Review, the authors describe the potential of computational analysis approaches to enable the discovery of more complex predictive biomarkers based on comprehensive analysis of large clinical and preclinical datasets and thus address this unmet need. Tue, 06 Jan 2026 00:00:00 -0800 Advances in the management of localized bladder cancers The management of localized bladder cancers is rapidly evolving. In this Review, the authors discuss diagnostic innovations, refinements in surgical approaches and novel intravesical or systemic treatments such as immunotherapies and antibody–drug conjugates, as well as future directions including bladder-sparing approaches for muscle-invasive disease and novel biomarkers for personalized treatment and follow-up. Mon, 05 Jan 2026 00:00:00 -0800 The actionable transcriptome: a framework for incorporating RNA sequencing into precision oncology RNA sequencing (RNA-seq) is increasingly being integrated into molecular tumour profiling but remains underutilized for clinical decision-making. This Perspective presents a framework for assessing the therapeutic, diagnostic and prognostic actionability of RNA-seq findings as well as an ‘actionable transcriptome’ list to help guide the application of RNA-seq findings in oncology practice. Mon, 05 Jan 2026 00:00:00 -0800 MajesTEC results with teclistamab in relapsed and/or refractory multiple myeloma MajesTEC results with teclistamab in relapsed and/or refractory multiple myeloma Fri, 02 Jan 2026 00:00:00 -0800 Vebreltinib effective in MET-amplified NSCLC Vebreltinib effective in MET-amplified NSCLC Fri, 02 Jan 2026 00:00:00 -0800 |
|
| ||
|
Development of a predictive model for lymph node metastasis in esophageal cancer using 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) semi-quantitative parameters and tumor biomarkers
Vol 16, No 6 (December 31, 2025): Survival analysis of small cell carcinoma of the esophagus: a 15-year retrospective study from a high-incidence region Vol 16, No 6 (December 31, 2025): First-line PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone for advanced esophageal and gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis of randomized controlled trials Vol 16, No 6 (December 31, 2025): The clinical efficacy and pathological assessment of neoadjuvant imatinib treatment in patients with primary gastrointestinal stromal tumors Vol 16, No 6 (December 31, 2025): mTLS status predicts survival benefit from adjuvant chemotherapy in gastric cancer patients treated with neoadjuvant therapy and surgery Vol 16, No 6 (December 31, 2025): Trifluridine/tipiracil (FTD/TPI) in advanced gastric cancer—a retrospective cohort study providing real-world survival and safety data from the United Kingdom Vol 16, No 6 (December 31, 2025): Parenteral nutrition versus enteral nutrition after gastric cancer surgery: a systematic review and meta-analysis of randomized controlled trials Vol 16, No 6 (December 31, 2025): Trends of mortality among patients with malignant neoplasms of digestive system in the United States from 2007 to 2021 Vol 16, No 6 (December 31, 2025): The effect of neoadjuvant chemoradiotherapy on perioperative outcomes in rectal cancer patients following stoma reversal—a retrospective cohort analysis Vol 16, No 6 (December 31, 2025): The optimal number of lymph nodes examined for rectal cancer patients undergoing neoadjuvant long-course chemoradiotherapy Vol 16, No 6 (December 31, 2025): Predicting bevacizumab efficacy: the emerging role of ACTL6B in colorectal cancer Vol 16, No 6 (December 31, 2025): A prognostic nomogram for colorectal cancer: integrating blood microbiome and clinical factors Vol 16, No 6 (December 31, 2025): Bibliometric analysis on the correlation between colorectal cancer and tumor microenvironment [2009–2024] Vol 16, No 6 (December 31, 2025): Efficacy and safety of fruquintinib in refractory metastatic colorectal cancer: a systematic review and meta-analysis Vol 16, No 6 (December 31, 2025): ZNF454-FSTL3 axis inhibits colorectal cancer progression by inhibiting HIF-1α-mediated glycolysis in hypoxia Vol 16, No 6 (December 31, 2025): Glutaryl-CoA dehydrogenase: a key biomarker linking lysine degradation to hepatocellular carcinoma metastasis and prognosis via NF-KB signaling pathway Vol 16, No 6 (December 31, 2025): Safety and efficacy of transcatheter chemoembolization combined with hepatic arterial infusion chemotherapy for unresectable primary liver cancer: a single-center prospective study Vol 16, No 6 (December 31, 2025): Efficacy and safety of tyrosine kinase inhibitors combined with sintilimab and transarterial chemoembolization in patients with Barcelona Clinic Liver Cancer stage B/C hepatocellular carcinoma: a pooled analysis Vol 16, No 6 (December 31, 2025): Predicting the prognosis of hepatocellular carcinoma after curative resection using a nomogram based on the ratio of prealbumin to platelet distribution width Vol 16, No 6 (December 31, 2025): Revisiting the role of postoperative adjuvant transarterial chemoembolization in hepatocellular carcinoma: a propensity score matching analysis Vol 16, No 6 (December 31, 2025): Survival outcomes of patients after liver transplantation for patients with hepatocellular carcinoma exceeding the Hangzhou criteria Vol 16, No 6 (December 31, 2025): Landscape targeted of therapy in advanced pancreatic adenocarcinoma: a network meta-analysis of randomized controlled trials [2010–2024] Vol 16, No 6 (December 31, 2025): Metformin reshapes the tumor microenvironment and enhances prognosis in invasive pancreatic ductal adenocarcinoma with diabetes mellitus Vol 16, No 6 (December 31, 2025): The value of lipid metabolism-related genes in pancreatic cancer immunotherapy and drug prediction Vol 16, No 6 (December 31, 2025): Lumbar centroid level subcutaneous fat volume increased performance of prognostic predictive model in digestive system cancers: a real-world cohort study Vol 16, No 6 (December 31, 2025): Hypercalcemia in metastatic pancreatic neuroendocrine tumor: a case report of ectopic 1,25 hydroxyvitamin D production by tumor cells and tumor-associated macrophages Vol 16, No 6 (December 31, 2025): Staged approach to overcome hyperbilirubinemia: tailored chemotherapy in liver metastases-a case report Vol 16, No 6 (December 31, 2025): Multidisciplinary team approach of treatment of a metastatic gastric carcinoma during pregnancy: a case report Vol 16, No 6 (December 31, 2025): Intraocular metastasis from an anal squamous cell carcinoma: a case report Vol 16, No 6 (December 31, 2025): Claudin 18.2 in gastroesophageal adenocarcinoma: prevalence, biomarker associations, and implications for equity Vol 16, No 6 (December 31, 2025): Right place right time: the role of immunotherapy in patients with locally advanced gastric/gastroesophageal junction adenocarcinoma Vol 16, No 6 (December 31, 2025): Potential of regorafenib in late-line treatment for refractory advanced gastric cancer Vol 16, No 6 (December 31, 2025): Erratum: The clinical value of spectral computed tomography reconstruction technology for the anatomy of the superior mesenteric artery in laparoscopic radical right hemicolectomy for colon cancer: a cross-sectional study Vol 16, No 6 (December 31, 2025): |
|
|
|
| ||
|
The Michigan Appropriateness Guide for Intravenous Catheters in Adult Patients With Cancer (MAGIC-ONC): Results From a Multispecialty Panel Using the RAND/UCLA Appropriateness Method
Annals of Internal Medicine, Volume 178, Issue 12_Supplement, Page S143-S177, December 2025. <br/> Tue, 04 Nov 2025 08:00:00 +0000 Trends in Cancer Incidence in Younger and Older Adults Annals of Internal Medicine, Volume 178, Issue 12, Page 1677-1687, December 2025. <br/> Tue, 04 Nov 2025 08:00:00 +0000 Primary Care Physician Time Spent in Patient Care: An Observational Study Using Electronic Health Record Logs Annals of Internal Medicine, Volume 178, Issue 12, Page 1688-1697, December 2025. <br/> Tue, 04 Nov 2025 08:00:00 +0000 Trends in and Predictors of Physician Attrition From Clinical Practice Across Specialties Annals of Internal Medicine, Volume 178, Issue 12, Page 1698-1708, December 2025. <br/> Tue, 04 Nov 2025 08:00:00 +0000 The Mediterranean Diet for Irritable Bowel Syndrome Annals of Internal Medicine, Volume 178, Issue 12, Page 1709-1717, December 2025. <br/> Tue, 04 Nov 2025 08:00:00 +0000 Step Accumulation Patterns and Risk for Cardiovascular Events and Mortality Among Suboptimally Active Adults Annals of Internal Medicine, Volume 178, Issue 12, Page 1718-1727, December 2025. <br/> Tue, 04 Nov 2025 08:00:00 +0000 Effectiveness of Recombinant Herpes Zoster Vaccine in the U.S. Medicare Population, 2018 to 2019, by Immunocompetence and Prior Receipt of Live Zoster Vaccine Annals of Internal Medicine, Volume 178, Issue 12, Page 1728-1736, December 2025. <br/> Tue, 04 Nov 2025 08:00:00 +0000 Palliative Care Educational App for Family Caregivers of Homebound Patients With Incurable Cancer Annals of Internal Medicine, Volume 178, Issue 12, Page 1737-1751, December 2025. <br/> Tue, 04 Nov 2025 08:00:00 +0000 Effectiveness of Psychological Therapies for Depression During the Perinatal Period Annals of Internal Medicine, Volume 178, Issue 12, Page 1752-1762, December 2025. <br/> Tue, 04 Nov 2025 08:00:00 +0000 Artificial Intelligence–Assisted Data Extraction With a Large Language Model: A Study Within Reviews Annals of Internal Medicine, Volume 178, Issue 12, Page 1763-1771, December 2025. <br/> Tue, 04 Nov 2025 08:00:00 +0000 How Would You Manage This Diabetic Patient With a Foot Infection? Grand Rounds Discussion From Beth Israel Deaconess Medical Center Annals of Internal Medicine, Volume 178, Issue 12, Page 1785-1792, December 2025. <br/> Tue, 04 Nov 2025 08:00:00 +0000 Ethical Issues in Organ Transplantation: A Position Paper From the American College of Physicians Annals of Internal Medicine, Volume 178, Issue 12, Page 1772-1778, December 2025. <br/> Tue, 04 Nov 2025 08:00:00 +0000 Quality Indicators for Screening and Surveillance of Colorectal Cancer in Adults: A Review of Performance Measures by the American College of Physicians Annals of Internal Medicine, Volume 178, Issue 12, Page 1779-1784, December 2025. <br/> Tue, 04 Nov 2025 08:00:00 +0000 Immigration Enforcement Tactics and Systemic Health Harms: The Ethical Imperative for Medical Advocacy Annals of Internal Medicine, Volume 178, Issue 12, Page 1793-1795, December 2025. <br/> Tue, 04 Nov 2025 08:00:00 +0000 Payment for Physician Services in the United States: Has a Reckoning Begun? Annals of Internal Medicine, Volume 178, Issue 12, Page 1796-1797, December 2025. <br/> Tue, 04 Nov 2025 08:00:00 +0000 Overdue: Delayed Revision of Institutional Review Board Policies Characterizing Pregnant Women After the Revised Common Rule Annals of Internal Medicine, Volume 178, Issue 12, Page 1798-1800, December 2025. <br/> Tue, 04 Nov 2025 08:00:00 +0000 Generations at Risk: Unveiling the Global Increase in Cancer at Both Ends of Adulthood Annals of Internal Medicine, Volume 178, Issue 12, Page 1801-1802, December 2025. <br/> Tue, 04 Nov 2025 08:00:00 +0000 Stepping Up Our Game: Longer Bouts of Activity to Boost Longevity Annals of Internal Medicine, Volume 178, Issue 12, Page 1803-1804, December 2025. <br/> Tue, 04 Nov 2025 08:00:00 +0000 Patient Q Annals of Internal Medicine, Volume 178, Issue 12, Page 1805-1806, December 2025. <br/> Tue, 04 Nov 2025 08:00:00 +0000 Beyond the Diagnosis: Finding the Person in the Patient Annals of Internal Medicine, Volume 178, Issue 12, Page 1807, December 2025. <br/> Tue, 04 Nov 2025 08:00:00 +0000 Patient Portal Panic Annals of Internal Medicine, Volume 178, Issue 12, Page 1808-1809, December 2025. <br/> Tue, 04 Nov 2025 08:00:00 +0000 TMI Annals of Internal Medicine, Volume 178, Issue 12, Page 1810-1811, December 2025. <br/> Tue, 04 Nov 2025 08:00:00 +0000 Revision of Research Abstracts Through the Editorial Process Annals of Internal Medicine, Volume 178, Issue 12, Page 1813-1816, December 2025. <br/> Tue, 04 Nov 2025 08:00:00 +0000 Trends in Dispensed Gabapentin Prescriptions in the United States, 2010 to 2024 Annals of Internal Medicine, Volume 178, Issue 12, Page 1816-1818, December 2025. <br/> Tue, 04 Nov 2025 08:00:00 +0000 Changes in Carbapenemase-Producing Carbapenem-Resistant Enterobacterales, 2019 to 2023 Annals of Internal Medicine, Volume 178, Issue 12, Page 1818-1821, December 2025. <br/> Tue, 04 Nov 2025 08:00:00 +0000 Management of Hyperglycemia in Hospitalized Patients Annals of Internal Medicine, Volume 178, Issue 12, Page 1821-1822, December 2025. <br/> Tue, 04 Nov 2025 08:00:00 +0000 |
ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 SITC 2025: Macrophage-targeting CAR monocytes Improve Immunotherapy Outcomes in Breast Cancer SITC 2025: Results from the Phase 1 / 2a AERIAL Trial Evaluating Lateral CAR-T LEU011 for the Treatment of Solid Tumors SITC 2025: Data Shows Promising Preclinical Results for SynKIR™-110 in Solid Tumors SITC 2025: Long-term Complete Responses of T-Cell Therapies for HPV-Related Cancers ESMO 2025: A ctDNA-guided Approach to Helps Personalize Adjuvant Chemotherapy Colon Cancer October 20, 2025 ESMO 2025: Circulating Tumor DNA (ctDNA)–guided Treatment in Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer October 20, 2025 ESMO 2025: Vimseltinib Demonstrates Statistically Significant and Clinically Meaningful Benefit in Patients Diagnosed with Tenosynovial Giant Cell Tumor October 20, 2025 ESMO 2025: Belzutifan Shrinks Rare Neuroendocrine Tumors and Improves Patients Symptoms October 20, 2025 ESMO 2025: Previously Treated Advanced Kidney Cancer Patients may Benefit from Targeted Therapies October 19, 2025 ESMO 2025: Higher Thymic Health Linked to Better Patients’ Response to Immunotherapy October 19, 2025 ESMO 2025: A New Generation of Antibody-drug Conjugates Demonstrates Unprecedented Promise in Early-Stage Breast Cancer October 19, 2025 ESMO 2025: First In Human Dose Escalation for TT125-802 Shows Durable Confirmed Responses in Non-small Cell Lung Cancer October 18, 2025 ESMO 2025: Zongertinib Shows a 77% ORR in Treatment-naïve Patients with Advanced HER2 Mutant NSCLC October 18, 2025 ESMO 2025: First Phase 1 Safety and Efficacy Data Presented of Izalontamab Brengitecan in Patients with Advanced Solid Tumors October 18, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 FDA’s Plan To Boost Biosimilar Drugs Could Stall at the Patent Office November 17, 2025 Agency, Adaptation, and Access: Hospitals Leveraging Locum Tenens to Bridge the Physician Gap November 14, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 Daiichi Sankyo Out-Licenses Investigational Agent DS-6051 to AnHeart Therapeutics December 19, 2018 How Meaningful Will Changes Be to Ethical Guidelines Following Jose Baselga’s Fall? October 9, 2018 Reversal of Fortune: How a Vilified Drug Became a Life-saving Agent in the ‘War’ Against Cancer November 30, 2013 |
ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide
November 20, 2025 Pediatric Oncology: Novel Treatment Proves ‘Miracle’ for 6-Year-Old with Leukemia Jiahui International Cancer Center Successfully Treats a 78-year-old Patient from New Zealand with Advanced CAR T-Cell Therapy SITC 2025: Data Shows Promising Preclinical Results for SynKIR™-110 in Solid Tumors Combination Treatment of Ianalumab + Ibrutinib May Help Some Patients to Discontinue Daily Therapy Liposomal Spherical Nucleic Acids Constructs Impact both Chemotherapeutic Delivery and Cell Targeting November 1, 2025 Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma Shows Positive Topline Results October 24, 2025 Study Identifies TRβ as a Targetable Driver in the Growth of Prostate Cancer October 21, 2025 ESMO 2025: A ctDNA-guided Approach to Helps Personalize Adjuvant Chemotherapy Colon Cancer October 20, 2025 ESMO 2025: Circulating Tumor DNA (ctDNA)–guided Treatment in Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer October 20, 2025 ESMO 2025: Vimseltinib Demonstrates Statistically Significant and Clinically Meaningful Benefit in Patients Diagnosed with Tenosynovial Giant Cell Tumor October 20, 2025 ESMO 2025: Belzutifan Shrinks Rare Neuroendocrine Tumors and Improves Patients Symptoms October 20, 2025 ESMO 2025: Previously Treated Advanced Kidney Cancer Patients may Benefit from Targeted Therapies October 19, 2025 ESMO 2025: A New Generation of Antibody-drug Conjugates Demonstrates Unprecedented Promise in Early-Stage Breast Cancer October 19, 2025 ESMO 2025: First In Human Dose Escalation for TT125-802 Shows Durable Confirmed Responses in Non-small Cell Lung Cancer October 18, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 FDA’s Plan To Boost Biosimilar Drugs Could Stall at the Patent Office November 17, 2025 Agency, Adaptation, and Access: Hospitals Leveraging Locum Tenens to Bridge the Physician Gap November 14, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 Daiichi Sankyo Out-Licenses Investigational Agent DS-6051 to AnHeart Therapeutics December 19, 2018 How Meaningful Will Changes Be to Ethical Guidelines Following Jose Baselga’s Fall? October 9, 2018 Reversal of Fortune: How a Vilified Drug Became a Life-saving Agent in the ‘War’ Against Cancer November 30, 2013 |
|
| ||
|
Arrowhead Enters Obesity Chat by Doubling Tirzepatide’s Weight Loss in Combo Study
Arrowhead heralded the results as proof of concept that inhibiting the Activin E pathway can improve body composition and enhance weight loss as compared to tirzepatide alone, particularly in patients with type 2 diabetes.
Takeda’s Commitment to Trial Representation is Shaping the Future of Clinical Research One way Takeda lives out its values is by striving to ensure that patients are aware of and can access the company’s clinical trials. Two employees from its research and development organization discuss why representation matters and the work their team is doing to benefit patients now and in the future.
Biohaven Notches Another Psychiatric Failure Months After Key FDA Rejection The major depressive disorder failure for BHV-7000 is the drug’s second, after Biohaven’s spinocerebellar ataxia treatment troriluzole was rejected by the FDA in November 2025.
Insmed Delivers ‘Rare Disappointment’ as Brinsupri Flops in Mid-Stage Rhinosinusitis Study Insmed pointed to a strong placebo response as the reason for the trial’s failure.
AC Immune’s Parkinson’s Immunotherapy Appears to Slow Disease Progression In a first for the Parkinson’s field, AC Immune’s immunotherapy has stabilized key biomarkers that suggest an effect on the disease’s course.
Structure Stock Soars as Oral GLP-1 Generates ‘Highly Competitive’ Weight Loss Structure’s aleniglipron elicited over 11% weight loss in a Phase II trial, sending the biotech’s stock up nearly 103% as markets closed on Monday.
Dyne’s Exon Skipper Delivers ‘Best Ever’ Functional Outcomes in Early DMD Study Dyne’s exon-skipping therapy zeleciment rostudirsen resulted in an approximately sevenfold increase in dystrophin levels at six months and elicited functional improvements that are the “best ever” for this treatment class, Stifel analysts said.
Bridging Formulation and Device: Integrated Supply Chain Strategies for U.S. Pharma Manufacturing The pharmaceutical supply chain and device development have become intricately linked. Harmonizing formulation development with drug delivery device design—and leveraging a single‐vendor ecosystem—can deliver significant time, cost, and regulatory advantages for US‑focused drug products, according to industry experts. Praxis Ends Epilepsy Study Early Due to Strong Results, Heads to FDA Praxis Precision Medicines has also announced a “successful” pre-NDA meeting with the FDA for its essential tremor drug candidate ulixacaltamide, for which an approval application is slated for early 2026.
Imvax Heads to FDA With 6-Month Survival Gain in Glioblastoma, Despite Endpoint Miss While Imvax’s autologous immunotherapy IGV-001 missed the primary endpoint of progression-free survival in a Phase IIb trial, the company will request a meeting with the FDA to discuss next steps for “synergistic” treatment.
Nouscom Highlights Potential of NOUS-209 to Intercept Cancer in Lynch Syndrome Carriers in Seminal Nature Medicine Publication CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection (AMR) HMNC Brain Health Presented Positive Phase 2b Data at American College of Neuropsychopharmacology Annual Meeting Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration AAVantgarde Completes Enrollment in LUCE-1 Phase 1/2 Clinical Trial of AAVB-081 for Usher Syndrome Type B-associated Retinitis Pigmentosa Hyundai Bioscience Confirms Entry into U.S. FDA Phase 2 Trials for Broad-Spectrum Antiviral ‘XAFTY’ Following 2026 Biotech Showcase Consensus Gradalis’ Vigil® Demonstrates Significant Survival Benefit in cTMB-H / HRP Ovarian Cancer Patients; Phase 2b VITAL Trial Analysis Published in JCO – Precision Oncology Aptar’s Nasal Vaccine Delivery Solutions Featured in CastleVax Phase II Clinical Trial of an Intranasal COVID-19 Vaccine Candidate Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101 Thryv Therapeutics Launches Pivotal Wave II Phase 2/3 Study in Long QT Syndrome Type 2 Ractigen Therapeutics Announces First Patient Dosed in Phase II Clinical Trial of RAG-17 for SOD1-ALS Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data Boehringer Ingelheim advances potential first-in-class IL-11 inhibitor to Phase II Clinical Research in Idiopathic Pulmonary Fibrosis Immunofoco Presents Phase I/IIa Data of IMC002 at ASCO GI 2026, Highlighting a Durable Complete Response Beyond One Year and a 66.7% ORR in Advanced GC/GEJ AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause Insilico Medicine Completes First Patient First Dose in BETHESDA: A Phase II Trial for Garutadustat (ISM5411), the Gut-restricted AI-driven PHD Inhibitor for the Treatment of Inflammatory Bowel Disease Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026 Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026 Encoded Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to ETX101 for the Treatment of Dravet Syndrome |
Moderna, Merck Show Long-Term Survival For mRNA-Keytruda Combo
The companies have an expansive clinical program for the mRNA neoantigen therapy intismeran autogene in combination with immuno-oncology heavyweight Keytruda.
AbbVie, Genmab’s Bispecific Misses Key Overall Survival Endpoint in Phase III Lymphoma Study Despite the late-stage miss, analysts maintained confidence in the Epkinly program, with Truist Securities saying the result “doesn’t waver our optimism” regarding the bispecific antibody’s ongoing frontline trial.
JPM26: Protagonist Has a $400M Decision To Make. It’s a No-Brainer Following rusfertide’s triumphant Phase III trial last year, Protagonist must decide how involved to be in future development. Hundreds of millions of dollars are on the line.
Lilly’s Path to $94B in Revenue Rests on Oral Obesity Market and Other 2026 Milestones The fierce rivalry between Novo Nordisk and Eli Lilly is alive and well, as the two companies are expected to face off with their new obesity pills this year.
Takeda’s Commitment to Trial Representation is Shaping the Future of Clinical Research One way Takeda lives out its values is by striving to ensure that patients are aware of and can access the company’s clinical trials. Two employees from its research and development organization discuss why representation matters and the work their team is doing to benefit patients now and in the future.
Ultragenyx Loses $1B in Market Value as Bone Drug Fails To Reduce Fractures With a pair of Phase III trial flops, Ultragenyx will explore cost reductions as analysts turn attention to an upcoming Angelman syndrome readout.
Neurocrine’s Valbenazine Fails Phase III Neurodevelopmental Disorder Trial Analysts said the outcome is disappointing because there are no approved treatments for dyskinetic cerebral palsy, but the setback had little impact on Neurocrine’s valuation.
AstraZeneca’s ATR Inhibitor Fails To Improve Survival in Phase III Lung Cancer Trial Ceralasertib is part of AstraZeneca’s ambitious plan to hit $80 billion in revenue by 2030.
Takeda’s $4B Nimbus Bet Pays Off With ‘Best-in-Class’ Phase III Plaque Psoriasis Data With zasocitinib, Takeda is looking to challenge Bristol Myers Squibb’s kinase inhibitor Sotyktu, for which the Japanese pharma is running a head-to-head study in plaque psoriasis. Takeda expects to file for zasocitinib’s FDA approval next year.
Lilly’s Obesity Pill Maintains Weight Loss as Estimated Approval Timelines Inch Closer Participants in a Phase III trial who switched to Eli Lilly’s orforglipron after 72 weeks of treatment with Wegovy or Zepbound largely maintained their weight loss for up to a year.
Nxera Pharma Reports Positive Results From Phase 3 Trial of Daridorexant in South Korea AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) New clinical data highlights CAPLYTA® (lumateperone) as a promising option for achieving remission in adults with major depressive disorder Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia Almirall Announces “LumiNE”, a Phase III Clinical Study Assessing the Efficacy of Lebrikizumab for the Treatment of Nummular Eczema TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide Ontario Pioneers Access to Treatment for Severe Alopecia Areata with Lilly’s Olumiant® HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet ImmunityBio Announces Positive Results Demonstrating ANKTIVA® as a Lymphocyte Stimulating Agent in Combination With Checkpoint Inhibitors in Non-Small Cell Lung Cancer Thryv Therapeutics Launches Pivotal Wave II Phase 2/3 Study in Long QT Syndrome Type 2 TROPION-Lung17 TROP2 Biomarker Directed Phase 3 Trial of DATROWAY® Initiated in Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer’s Disease in the Journal of Prevention of Alzheimer’s Disease FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor Kailera Therapeutics Announces First Participants Randomized in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide (KAI-9531) Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook Lynk Pharmaceuticals Announces Positive Phase III Topline Data of Zemprocitinib (LNK01001) in Rheumatoid Arthritis Bristol Myers Squibb Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) |
AbbVie, Genmab’s Bispecific Misses Key Overall Survival Endpoint in Phase III Lymphoma Study
Despite the late-stage miss, analysts maintained confidence in the Epkinly program, with Truist Securities saying the result “doesn’t waver our optimism” regarding the bispecific antibody’s ongoing frontline trial.
JPM26: Protagonist Has a $400M Decision To Make. It’s a No-Brainer Following rusfertide’s triumphant Phase III trial last year, Protagonist must decide how involved to be in future development. Hundreds of millions of dollars are on the line.
Trump Must Make Biotech Innovation a National Priority An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation threaten the U.S.’s half-century-long dominance in the biotech sector.
JPM26: Pfizer Fast-Tracks Obesity Programs in Race Against Patent Cliff Facing the loss of exclusivity on key products, Pfizer has pulled forward its lead obesity asset into Phase III and targeted a 2028 launch. CEO Albert Bourla explained the pharma’s strategy at J.P. Morgan on Monday.
Lung Cancer Trial to Proceed After FDA Releases Hold on Merck, Daiichi’s ADC The FDA initially placed the Phase III IDeate-Lung02 study on hold due to a “higher than expected” number of deaths in patients treated with ifinatamab deruxtecan.
JPM26: BMS’s Early-Stage Bets Are Happening Now, Amid Pharma’s Late-Stage Frenzy Mature biopharma deals are stealing all the headlines, but Bristol Myers Squibb’s Robert Plenge says the company’s deals with insitro, Orbital and more are building the future.
From Nuclear Winter to Renewal: Biotech Investing for 2026 In this episode of Denatured, Jennifer C. Smith-Parker speaks to Maha Katabi, general partner at Sofinnova Investments and Andrew Lam, managing director, head of Biotech Private Equity at Ally Bridge Group, about how M &A dynamics, dealmaking and global partnerships are reshaping portfolio valuations and paths to growth in 2026.
Biotech Investors Bet on a 2026 Rebound as Deal Activity Accelerates After a prolonged funding chill, investors say 2026 is shaping up for continued dealmaking and diversified bets beyond oncology and immunology.
Arrowhead Enters Obesity Chat by Doubling Tirzepatide’s Weight Loss in Combo Study Arrowhead heralded the results as proof of concept that inhibiting the Activin E pathway can improve body composition and enhance weight loss as compared to tirzepatide alone, particularly in patients with type 2 diabetes.
Lilly’s Path to $94B in Revenue Rests on Oral Obesity Market and Other 2026 Milestones The fierce rivalry between Novo Nordisk and Eli Lilly is alive and well, as the two companies are expected to face off with their new obesity pills this year.
D3 Bio Receives U.S. FDA Clearance for Two IND Applications, Enabling Phase 1 Trial of D3S‑003 and Phase 2 Combination Study of Elisrasib (D3S‑001) with D3S‑002 Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) New clinical data highlights CAPLYTA® (lumateperone) as a promising option for achieving remission in adults with major depressive disorder ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCG OrsoBio Announces Nature Medicine Publication Establishing Clinical and Mechanistic Validation of First-in-Class LXR Inverse Agonist TLC-2716 for the Treatment of Serious Metabolic Diseases Nouscom Highlights Potential of NOUS-209 to Intercept Cancer in Lynch Syndrome Carriers in Seminal Nature Medicine Publication Dymicron Announces First Patient Enrolled in Triadyme-C IDE Clinical Trial CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection (AMR) HMNC Brain Health Presented Positive Phase 2b Data at American College of Neuropsychopharmacology Annual Meeting Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia AAVantgarde Completes Enrollment in LUCE-1 Phase 1/2 Clinical Trial of AAVB-081 for Usher Syndrome Type B-associated Retinitis Pigmentosa Almirall Announces “LumiNE”, a Phase III Clinical Study Assessing the Efficacy of Lebrikizumab for the Treatment of Nummular Eczema First Patients in the UK Receive Doses of Blue Earth Therapeutics’ Investigational Radiopharmaceutical Therapy Lutetium (177Lu) rhPSMA-10.1 Injection for Metastatic Castrate Resistant Prostate Cancer Hyundai Bioscience Confirms Entry into U.S. FDA Phase 2 Trials for Broad-Spectrum Antiviral ‘XAFTY’ Following 2026 Biotech Showcase Consensus TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide Gradalis’ Vigil® Demonstrates Significant Survival Benefit in cTMB-H / HRP Ovarian Cancer Patients; Phase 2b VITAL Trial Analysis Published in JCO – Precision Oncology |
|
| ||
|
FDA approves amivantamab and hyaluronidase-lpuj for subcutaneous injection
On December 17, 2025, the Food and Drug Administration approved amivantamab and hyaluronidase-lpuj (Rybrevant Faspro, Janssen Biotech, Inc.) for subcutaneous injection for adult patients across all indications approved for the intravenous formulation of amivantamab (Rybrevant, Janssen Biotech, Inc.). See the prescribing information for the specific indications.
Wed, 17 Dec 2025 00:00:02 -0800
FDA grants regular approval to rucaparib for metastatic castration-resistant prostate cancer On December 17, 2025, the Food and Drug Administration approved rucaparib (Rubraca, pharmaand GmbH) for adults with a deleterious BRCA mutation (BRCAm) (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) previously treated with an androgen receptor-directed therapy. Patients should be selected for therapy using an FDA-approved companion diagnostic (CDx).
Wed, 17 Dec 2025 00:00:02 -0800
FDA approves fam-trastuzumab deruxtecan-nxki with pertuzumab for unresectable or metastatic HER2-positive breast cancer On December 15, 2025, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) in combination with pertuzumab for the first-line treatment of adults with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer as determined by an FDA-approved test.
Mon, 15 Dec 2025 00:00:02 -0800
FDA approves niraparib and abiraterone acetate plus prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer On December 12, 2025, the Food and Drug Administration approved niraparib and abiraterone acetate (Akeega, Janssen Biotech, Inc.) with prednisone for adults with deleterious or suspected deleterious BRCA2-mutated (BRCA2m) metastatic castration-sensitive prostate cancer (mCSPC), as determined by an FDA-approved test.
Fri, 12 Dec 2025 00:00:02 -0800
FDA approves lisocabtagene maraleucel for relapsed or refractory marginal zone lymphoma On December 4, 2025, the Food and Drug Administration approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company) for adults with relapsed or refractory marginal zone lymphoma (MZL) who have received at least two prior lines of systemic therapy
Thu, 04 Dec 2025 00:00:02 -0800
FDA grants traditional approval to pirtobrutinib for chronic lymphocytic leukemia and small lymphocytic lymphoma On December 3, 2025, the Food and Drug Administration granted traditional approval to pirtobrutinib (Jaypirca, Eli Lilly and Company) for adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor. In 2023, FDA granted accelerated approval to pirtobrutinib for adults with CLL/SLL who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.
Wed, 03 Dec 2025 00:00:02 -0800
FDA approves durvalumab for resectable gastric or gastroesophageal junction adenocarcinoma On November 25, 2025, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, followed by single agent durvalumab, for adults with resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).
Tue, 25 Nov 2025 00:00:02 -0800
FDA approves pembrolizumab with enfortumab vedotin-ejfv for muscle invasive bladder cancer On November 21, 2025, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) with enfortumab vedotin-ejfv (Padcev, Astellas Pharma) as neoadjuvant treatment followed by adjuvant treatment after cystectomy for adults with muscle invasive bladder cancer (MIBC) who are ineligible for cisplatin.
Fri, 21 Nov 2025 00:00:02 -0800
FDA grants traditional approval to tarlatamab-dlle for extensive stage small cell lung cancer On November 19, 2025, the Food and Drug Administration granted traditional approval to tarlatamab-dlle (Imdelltra, Amgen Inc.) for adults with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. Tarlatamab-dlle received accelerated approval for this indication in 2024.
Wed, 19 Nov 2025 00:00:02 -0800
FDA grants accelerated approval to sevabertinib for non-squamous non-small cell lung cancer On November 19, 2025, the Food and Drug Administration granted accelerated approval to sevabertinib (Hyrnuo, Bayer HealthCare Pharmaceuticals Inc.), a kinase inhibitor, for adults with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy.
Wed, 19 Nov 2025 00:00:02 -0800
FDA grants traditional approval to daratumumab and hyaluronidase-fihj for newly diagnosed light chain amyloidosis On November 19, 2025, the Food and Drug Administration granted traditional approval to daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech Inc.) with bortezomib, cyclophosphamide, and dexamethasone (VCd) for newly diagnosed light chain (AL) amyloidosis. FDA granted accelerated approval for this indication in 2021.
Wed, 19 Nov 2025 00:00:02 -0800
FDA approves selumetinib for adults with neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas On November 19, 2025, the Food and Drug Administration approved selumetinib (KOSELUGO, AstraZeneca Pharmaceuticals LP) for adults with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). FDA previously approved selumetinib capsules and granules for pediatric patients 1 year of age and older for this indication.
Wed, 19 Nov 2025 00:00:02 -0800
FDA approves epcoritamab-bysp for follicular lymphoma indications On November 18, 2025, the Food and Drug Administration approved epcoritamab-bysp (Epkinly, Genmab US, Inc.) with lenalidomide and rituximab for relapsed or refractory follicular lymphoma (FL). The FDA also granted traditional approval to epcoritamab-bysp as monotherapy for relapsed or refractory FL after two or more lines of systemic therapy (epcoritamab-bysp was granted accelerated approval for this indication in 2024).
Tue, 18 Nov 2025 00:00:02 -0800
FDA approves new interchangeable biosimilar to Perjeta On November 13, 2025, the Food and Drug Administration approved Poherdy (pertuzumab-dpzb, Shanghai Henlius Biologics Co. Ltd.) as an interchangeable biosimilar to Perjeta (pertuzumab, Genentech Inc.). This is the first approval of a biosimilar for Perjeta.
Thu, 13 Nov 2025 00:00:02 -0800
FDA approves ziftomenib for relapsed or refractory acute myeloid leukemia with a NPM1 mutation On November 13, 2025, the Food and Drug Administration approved ziftomenib (Komzifti, Kura Oncology, Inc.), a menin inhibitor, for adults with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation who have no satisfactory alternative treatment options.
Thu, 13 Nov 2025 00:00:02 -0800
FDA approves daratumumab and hyaluronidase-fihj for high-risk smoldering multiple myeloma On November 6, 2025, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) for adults with high-risk smoldering multiple myeloma (SMM).
Thu, 06 Nov 2025 00:00:02 -0800
FDA approves revumenib for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation On October 24, 2025, the Food and Drug Administration approved revumenib (Revuforj, Syndax Pharmaceuticals, Inc.), a menin inhibitor, for relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 (NPM1) mutation in adult and pediatric patients 1 year and older who have no satisfactory alternative treatment options.
Fri, 24 Oct 2025 00:00:02 -0700
FDA approves belantamab mafodotin-blmf for relapsed or refractory multiple myeloma On October 23, 2025, the Food and Drug Administration approved belantamab mafodotin-blmf (Blenrep, GlaxoSmithKline), a B-cell maturation antigen (BCMA)-directed antibody and microtubule inhibitor conjugate, with bortezomib and dexamethasone for adults with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent.
Thu, 23 Oct 2025 00:00:02 -0700
FDA approves cemiplimab-rwlc for adjuvant treatment of cutaneous squamous cell carcinoma On October 8, 2025, the Food and Drug Administration approved cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals Inc.) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiation.
Wed, 08 Oct 2025 00:00:02 -0700
FDA approves lurbinectedin in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs for extensive-stage small cell lung cancer On October 2, 2025, the Food and Drug Administration approved lurbinectedin (Zepzelca, Jazz Pharmaceuticals, Inc.) in combination with atezolizumab (Tecentriq, Genentech Inc.) or atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech Inc.) for the maintenance treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first-line induction therapy with atezolizumab or atezolizumab and hyaluronidase-tqjs, carboplatin, and etoposide.
Thu, 02 Oct 2025 00:00:02 -0700
FDA approves imlunestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer On September 25, 2025, the Food and Drug Administration approved imlunestrant (Inluriyo, Eli Lilly and Company), an estrogen receptor antagonist, for adults with estrogen receptor (ER)-positive, human epidermal growth factor 2 (HER2)-negative, estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.
Thu, 25 Sep 2025 00:00:02 -0700
FDA approves pembrolizumab and berahyaluronidase alfa-pmph for subcutaneous injection On September 19, 2025, the Food and Drug Administration approved pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) for subcutaneous injection for adult and pediatric (12 years and older) solid tumor indications approved for the intravenous formulation of pembrolizumab (Keytruda, Merck). See the prescribing information for the specific indications.
Fri, 19 Sep 2025 00:00:02 -0700
FDA approves selumetinib for pediatric patients 1 year of age and older with neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas On September 10, 2025, the Food and Drug Administration approved selumetinib (KOSELUGO, AstraZeneca Pharmaceuticals LP) granules and capsules for pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). FDA previously approved selumetinib capsules for pediatric patients 2 years of age and older with NF1 who have symptomatic, inoperable PN.
Wed, 10 Sep 2025 00:00:02 -0700
FDA approves gemcitabine intravesical system for non-muscle invasive bladder cancer On September 9, 2025, the Food and Drug Administration approved gemcitabine intravesical system (Inlexzo, Janssen Biotech, Inc.) for adults with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. Gemcitabine intravesical system is co-packaged with a urinary catheter and stylet used for insertion through the urinary catheter into the bladder.
Tue, 09 Sep 2025 00:00:02 -0700
|
Nanoparticles hijack calvarial immune cells for CNS drug delivery and stroke therapy.
Cell. 2026 Jan 16:S0092-8674(25)01421-7. doi: 10.1016/j.cell.2025.12.008. Gao X, Liu X, Wang N, Cui C, Liu W, Yang M, Li Q, Ou Y, Ning A, Wei X, Zhang M, Qiu S, Lei Y, Fu D, Li H, Sun L, Lu M, Zhang M, Wang Y Retraction Note: Antibodies against endogenous retroviruses promote lung cancer immunotherapy. Nature. 2026 Jan 14. doi: 10.1038/s41586-026-10104-7. Ng KW, Boumelha J, Enfield KSS, Almagro J, Cha H, Pich O, Karasaki T, Moore DA, Salgado R, Sivakumar M, Young G, Molina-Arcas M, de Carné Trécesson S, Anastasiou P, Fendler A, Au L, Shepherd STC, Martínez-Ruiz C, Puttick C, Black JRM, Watkins TBK, Kim H, Shim S, Faulkner N, Attig J, Veeriah S, Magno N, Ward S, Frankell AM, Al Bakir M, Lim EL, Hill MS, Wilson GA, Cook DE, Birkbak NJ, Behrens A, Yousaf N, Popat S, Hackshaw A; TRACERx Consortium; CAPTURE Consortium; Hiley CT, Litchfield K, McGranahan N, Jamal-Hanjani M, Larkin J, Lee SH, Turajlic S, Swanton C, Downward J, Kassiotis G Global burden of amphetamine, cannabis, cocaine and opioid use in 204 countries, 1990-2023: a Global Burden of Disease Study. Nat Med. 2026 Jan 16. doi: 10.1038/s41591-025-04137-0. Kang J, Kim HJ, Kim MS; GBD 2023 Substance Use Collaborators; Shin JI, Yon DK Single-cell screens identify ADAM12 as a fibroblast checkpoint impeding anti-tumor immunity. Cancer Cell. 2026 Jan 15:S1535-6108(25)00552-5. doi: 10.1016/j.ccell.2025.12.018. Li J, Liu H, Guo Q, Zhang Y, Li J, Diao T, Zheng L, Deng Z, Yang Y, Chen X, Qin S, Li J, He Y, He W, Liu D, Bo Y, Liu C, Lu H, Fan H, Hu X, Peng J, Zhu L, Xi JJ, Wang D, Zhang Z Nucleotide metabolic rewiring enables NLRP3 inflammasome hyperactivation in obesity. Science. 2026 Jan 15;391(6782):eadq9006. doi: 10.1126/science.adq9006. Epub 2026 Jan 15. Liu D, Zhou C, Wang X, Luo Z, Xu R, Huo S, Guo L, Luo X, Yang S, Click A, Vancil J, Barajas P, Mijares V, Baniasadi H, Yan N, Rehwinkel J, Hancks DC, Chen EH, Liang S, Zhong Z The ubiquitin ligase KLHL6 drives resistance to CD8+ T cell dysfunction. Nature. 2026 Jan 14. doi: 10.1038/s41586-025-09926-8. Cheng H, Su Y, Pan X, Xu Y, Xie E, Du J, Chen DG, Dai X, Gottardo R, Greenberg PD, Li G Cross-sectional study of prepared foods sold in Indonesian school canteens to inform childhood obesity programs and policies. J Nutr Sci. 2026 Jan 8;15:e7. doi: 10.1017/jns.2025.10068. eCollection 2026. Sijangga MO, Hositanisita H, Lewis EC, Hadi H, Matsuzaki M, Surkan PJ, Kang Y, Purnamasari SD, Kurniasari Y, Gittelsohn J Deaths potentially averted by small changes in physical activity and sedentary time: an individual participant data meta-analysis of prospective cohort studies. Lancet. 2026 Jan 13:S0140-6736(25)02219-6. doi: 10.1016/S0140-6736(25)02219-6. Ekelund U, Tarp J, Ding D, Sanchez-Lastra MA, Dalene KE, Anderssen SA, Steene-Johannessen J, Hansen BH, Morseth B, Hopstock LA, Sagelv E, Nordström P, Nordström A, Hagströmer M, Dohrn IM, Diaz KM, Hooker S, Howard VJ, Lee IM, Fagerland MW Safety and equity in scaling minimally invasive surgery worldwide in 109 countries using cholecystectomy as a tracer procedure: a prospective cohort study. Lancet Glob Health. 2026 Feb;14(2):e199-e212. doi: 10.1016/S2214-109X(25)00476-0. NIHR Global Health Research Unit on Global Surgery and the GlobalSurg Collaborative Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits. Lancet. 2026 Jan 14:S0140-6736(25)02105-1. doi: 10.1016/S0140-6736(25)02105-1. Nauck MA, Tuttle KR, Tschöp MH, Blüher M Association of cholesterol, high-density lipoprotein and glucose (CHG) index with mortality risk in metabolic dysfunction-associated steatotic liver disease (MASLD) adults: results from two prospective cohorts. Cardiovasc Diabetol. 2026 Jan 17. doi: 10.1186/s12933-026-03079-2. Zhu H, Liu L, Yang S, Fu Y, Pan Y, Fu Q, Du F, Zhou X Salivary fluoride bioavailability after application of fluoride varnishes: A randomized clinical study. Braz Dent J. 2026 Jan 12;36:e65555. doi: 10.1590/0103-644020256555. eCollection 2026. Lopes MSS, Rezende LVM, Paz EC, Campos G Double aneuploidy: the frequency of XXY in males with Down's syndrome. Am J Hum Genet. 1969 Jul;21(4):352-9. Hecht F, Nievaard JE, Duncanson N, Miller JR, Higgins JV, Kimberling WJ, Walker FA, Smith GS, Thuline HC, Tischler B Metabolic dysfunction-associated steatotic liver disease accelerates pancreatic cancer progression and metastasis via the macrophage migration inhibitory factor-CD44 axis. Signal Transduct Target Ther. 2026 Jan 16;11(1):32. doi: 10.1038/s41392-025-02562-8. Yu Q, Song H, Shi XY, Zhu L, Liang Y, Gong RN, Dong XW, Liu SL, Wang HZ, Wang YL, Cui JF, Yang XN, Chen Y, Gao C, Yang Z, Zhu QT, Li C, Zhang H, Ying JE, Zheng MF, Tian YT, Hu HT, Shao XX, Li Y, Mo MG, Lu Y, Ma Z, Fu SL, Niu QH, Liao YY, Zhao CY, Liu X, Saluja AK, Wang JG, Li XY, Guo SY, Wang WH, Wang S, Liu B, Lu GT, Ren H Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2026 Jan 13:S0140-6736(25)01811-2. doi: 10.1016/S0140-6736(25)01811-2. Lu S, Wang J, Yang N, Lv D, Chen L, Wu L, Li X, Sun L, Yu Y, Jin B, Yang L, Guo Y, Xu H, Yi T, Zeng A, Dong X, Chen J, Wang Z, Niu H, Cheng Y, Pan P, Deng P, Pan H, Min X, Bai J, Liu L, Zhang T, Li J, Fan S, Shi MM, Mok T, Su W; SACHI Study Group Prognostic effect of triglyceride glucose-related parameters on all-cause and cardiovascular mortality in individuals with cardiovascular-kidney-metabolic syndrome: evidence from international multi-cohort studies. Cardiovasc Diabetol. 2026 Jan 19. doi: 10.1186/s12933-025-03057-0. Li Z, Wu Y, Yang Y, Wang L, Dou S, Sun F, Fan X The predictive value of C-reactive protein-triglycerides-glucose index-waist-to-height ratio for stroke: a nationwide cohort study. Cardiovasc Diabetol. 2026 Jan 17;25(1):18. doi: 10.1186/s12933-025-03065-0. Zhou Z, Yang J, Hou J, Zhang L CD4+ T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy. Nat Med. 2026 Jan 15. doi: 10.1038/s41591-025-04121-8. Ho M, Paruzzo L, Noll JH, Stella F, Devi P, Ndeupen S, Day YA, Chen GM, Cohen IJ, Ramirez-Fernandez A, Waxman A, Kapur S, Chen F, Xu R, Huff A, Jarocha D, Patel V, Bochi-Layec AC, Ramasubramanian R, Liu S, Bouvier R, de Souza VB, Patel H, Li Z, Carturan A, Michener P, Hopkins CR, Koucky O, Minehart J, Dimitri A, Nabar NR, Hasanali ZS, Ciccarelli BT, Hung P, Williams E, Bartoszek R, Lavorando M, Mohan S, Gonzalez VE, Porazzi P, Bhoj VG, Apostolidis SA, Vogl DT, Porter DL, Scholler J, Diorio C, Roche AM, Everett JK, Bushman FD, Nathanson KL, Stadtmauer EA, Susanibar-Adaniya SP, Garfall AL, Ruella M, Cohen AD, Fraietta JA Multi-omics profiling reveals CKM syndrome severity as a gradient risk factor for cancer: A prospective cohort study. Metabolism. 2026 Jan 14:156508. doi: 10.1016/j.metabol.2026.156508. Huang Y, Zhang Y, Zhang Y, Ye Z, Yang S, Gan X, Wu Y, Zhang Y, Qin X Genetic engineering of systemically injectable oncolytic viruses for pyroptosis-accelerated cancer virotherapy. Nat Cancer. 2026 Jan 16. doi: 10.1038/s43018-025-01078-y. Chen X, Yang M, Chen Y, Zhang Y, Wang S, Meng J, Zhu Z, Li W, Wei W, Ping Y, Liang T |
|